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Pathological bone loss in human disease such as arthritis is largely due to excessive 
osteoclast recruitment as a consequence of localized inflammation. Innate immune cells, namely 
neutrophils and macrophages, infiltrate the joint space and release pro-inflammatory cytokines as 
well as proteases to drive local tissue damage and inflammation. Importantly, IL-1 and TNF- in 
particular act on the synovial fibroblasts as well as directly on osteoclast precursors to potently 
augment osteoclast differentiation and thus bone resorption. Current therapeutics to treat 
pathological bone loss are widely unsuccessful at targeting both the resorptive and inflammatory 
components of disease. We have previously demonstrated that phospholipase C gamma-2 
(PLCγ2) regulates both the osteoclast and innate immune cell functions. PLCγ2-/- mice are 
osteopetrotic resulting from defective OC formation and are protected from inflammatory bone 
loss due to impaired innate immune responses. While PLCγ2 function can be specifically 
repressed in the osteoclast via SH2 domain targeting, this approach does not block inflammation 
in vivo. Thus we sought to identify specific downstream targets of PLC2 that could regulate 
both the osteoclast and innate immune responses in arthritis. 
 viii 
 By a gene array approach, we identified the previously undescribed protein Tmem178 as 
a novel PLC2 effector whose expression is highly induced by RANKL stimulation, integrin-
mediated adhesion, and TLR activation in WT but not PLC2-/-macrophages. Importantly, 
Tmem178 expression is confined to macrophages and osteoclasts and not in other bone marrow-
derived cells or immune cell types such as T cells. In surprising contrast to the osteopetrotic 
phenotype of PLC2-/- mice, Tmem178-/- mice are osteopenic in basal conditions and are more 
susceptible to inflammatory bone loss, owing to enhanced osteoclast formation. We also find that 
Tmem178-null mice succumb faster to endotoxin-induced sepsis due to an increase in 
inflammatory cytokine production by macrophages. Mechanistically, Tmem178 localizes to the 
endoplasmic reticulum membrane where it interacts with the Ca2+-sensing protein Stim1. In the 
ER, Tmem178 acts to restrain Ca2+ release, thus controlling activation of the transcription factor 
NFAT which is central to both osteoclast differentiation and pro-inflammatory cytokine 
production. Importantly, downregulation of Tmem178 is observed in human CD14+ monocytes 
exposed to plasma from systemic juvenile idiopathic arthritis patients. This defective Tmem178 
expression correlates with augmented osteoclastogenesis in vitro and erosive disease in vivo, 
suggesting that Tmem178 may also play a fundamental role in controlling arthritic disease in 
humans. In sum, this dissertation identifies the first known function of Tmem178 in any cell type 
and positions Tmem178 as an essential regulatory component in both the inflammatory and 
erosive arms of pathological bone loss.    
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Chapter 1. Introduction 
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1.1 Background 
Part I. The osteoclast and bone remodeling 
 The musculoskeletal system, comprised of bone, cartilage, and muscle, serves three 
essential functions in the organism. The mechanical function of the skeleton is required to 
mediate mobility and stability of the organism. Secondly, the skeleton serves to harbor and shield 
the bone marrow within the vertebrae and long bones, as well as protect the internal organs 
housed within the rib cage and skull. Lastly, the bone itself is a reservoir of mineral stores, 
namely calcium and phosphate, which are released from the skeleton during bone turnover and 
regulate whole-body metabolism. In these ways, the skeleton is a dynamic organ which exerts 
not only its obvious mechanical and structural functions, but also participates in cross-talk with 
the endocrine, immune, digestive, and nervous systems (1, 2).  
 The bone is comprised of an inorganic and organic matrix. The latter is made up 
primarily of type I collagen, as well as numerous growth factors including osteopontin, bone 
sialoprotein, osteonectin, osteocalcin, and glycosaminoglycans. The inorganic matrix of the 
bone, which is laid down on top of the organic matrix, is comprised of carbonated 
hydroxyapatite. Deposition of these organic and inorganic is carried out by osteoblasts (OB) 
derived from mesenchymal progenitors (MPs). OBs both form and mineralize the skeleton 
during embryonic and postnatal development, skeletal remodeling and bone turnover throughout 
life (3).  In vivo, mature OBs are characterized by their cuboidal morphology on the bone surface 
which distinguishes them from flat, bone-lining cells. In vivo, it is believe that these mature OBs 
form the bone, while the more immature OBs produce RANKL, a factor required for osteoclast 
(OC) differentiation (4).  The OC is the sole bone-resorbing cell that is required for proper 
shaping of the bone and bone turnover (5). The coupling of OC and OB activity is central to 
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skeletal formation and maintenance. As the body of this work focuses on the OC, OB 
differentiation and function will not be discussed in detail but are well-described in detail in 
references (6-8).  
Osteoclasts and skeletal resorption 
 Osteoclasts (OCs) are the unique multinucleated, bone-resorbing cells that form from the 
fusing of mononuclear precursors (9). As depicted in Figure 1.1, OCs originate from 
hematopoietic precursors in the bone marrow which first encounter the cytokine macrophage 
colony stimulating factor (M-CSF) which pushes the precursors to the common myeloid 
progenitor (CMP). M-CSF supports the proliferation and survival of the myeloid precursors and 
also upregulates expression of receptor activator of NF-kB (RANK), the receptor for RANK 
ligand (RANKL), the key osteoclastogenic cytokine (10).  Importantly, OBs present RANKL on 
their surface, and direct interaction of OB with OC precursors is the main driver of OC 
differentiation (11, 12). Mononuclear preOC begin expressing tartrate resistant acid phosphatase 
(TRAP), which is commonly used as a marker of OC both in vitro and in vivo. These 
mononuclear preOCs then fuse to form large, multi-nucleated OC which are fully mature when 
attached to the bone surface (13, 14). It is believed that in vivo OCs have a relatively short life 
span and undergo apoptosis following bone resorption, although the inability to perform lineage 
tracing experiments of OCs in vivo has limited the complete understanding of this cell type. OCs 
are mature and active on the bone surface where they polarize and adhere tightly to the bone via 
v3 integrin attachment. v3 integrin is required for proper bone resorption and specifically 
recognizes bone matrix proteins including fibronectin and osteopontin to form a tight sealing 
zone; it is within this sealing zone that the OC resorbs the bone (15-19).  
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 After the mature OC attaches to the bone and establishes the sealing zone, the ruffled 
border structure is formed. The OC uses vesicle-mediated secretion of proteases and proteinases 
to resorb the bone. The fusion of these vesicles with the cell’s plasma membrane forms the 
appearance of a ruffled border made up of long projections of the plasma membrane into the 
bone matrix (20). Following the formation of the ruffled border, the OC first resorbs the 
inorganic matrix of the bone. OCs express protein pumps and chloride channels to form HCl in 
the resorptive lacunae and dissolve the hydroxyapatite of the bone (21-23). The organic matrix of 
the bone is then dissolved by proteolytic enzymes, namely matrix metalloproteinase 9 and 
cysteine proteases, which break down collagen (24). Cathepsin K is particularly required for 
resorption of the organic matrix, as the null mice present with severe osteopetrosis owing to 
defective resorption (25-27). Interestingly, Cathepsin K is released in discrete lysosomal vesicles 
independent of MMP9, although the exact regulatory mechanisms of Cathepsin K-containing 
vesicles are not yet understood (28). Following resorption, the OC must also remove the 
degradation products from the resorptive lacunae. Collagen fibers and calcium are taken up by 
the OC by vesicle-mediated endocytosis, and released from the top of the cell via transcytosis on 
the opposite side of the ruffled border. 
Bone remodeling 
The term “bone remodeling” is used to describe healthy skeletal turnover that occurs in adult 
organisms. This resorption of old bone and replacement with new bone is required to ensure 
skeletal integrity throughout life and is also required for bone healing in the instance of fracture 
or injury. Importantly, OC and OB functions are coupled during bone remodeling so that bone 
resorption and deposition are synchronized and equilibrated (Figure 1.2). Dysregulation of this 
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coupling underlies skeletal pathologies such as osteoporosis. Bone remodeling is broken down 
into 3 steps: initiation, transition, and termination (29, 30).  
 The initiation of bone remodeling can be spurred by numerous physiological changes 
including hormonal changes, deficits in serum calcium, mechanical load, or fractures in the bone. 
First, OC precursors must be recruited to the bone in response to chemoattractants including 
CCL2, also known as monocyte chemoattractant protein 1 (MCP-1) (31, 32). CCL2, which 
engages CCR2 or CCR4 on the OC precursor, is especially important and prevalent during 
inflammatory conditions, as its expression by OBs is induced by TNF- and IL-1. Additionally, 
vascular endothelial cells in the bone as well as OBs can produce stromal derived growth factor 
(SDF-1) which binds to CXCR4 on OC precursors (33, 34). After being recruited to the site of 
bone remodeling, OC precursors are mature and active on the bone surface, leading to the 
transition phase of remodeling.  
 During the transition phase of bone remodeling, OC activity is coupled to OB bone 
deposition. While resorbing the bone, the OC initiates the release of bone-derived growth factors 
to stimulate the OB. These factors include TFG, BMPs, and insulin-like growth factor II (IGF-
II) (35, 36).  Some molecules produced by the OCs themselves may also act on OBs. For 
example, sphingosine 1-phosphate (S1P) is secreted by OCs and can signal to OBs to enhance 
their recruitment and survival (37). The induction of OB activity also suppresses OC activity.  
Specifically, OBs express EphB4 which binds to ephrin B2 on the OC, inducing bi-directional 
signaling to promote OB proliferation while suppressing osteoclastogenesis (38). Ultimately, 
OCs undergo apoptosis during the transition phase while bone deposition predominates.  
During the termination phase, OBs actively form new bone, a slow process which can last 
approximately 3 months in humans. During this phase, OC differentiation and activity must be 
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suppressed to allow for matrix deposition. For this purpose, OBs produce osteoprotegerin (OPG), 
the soluble decoy receptor for RANKL. OPG production by the OBs is largely turned on through 
both NOTCH and Wnt signaling pathways (39, 40).  Mice lacking OPG present with 
osteoporosis due to excessive bonne resorption (41). At the conclusion of the termination phase, 
OBs are believed to have 3 possible fates: undergo apoptosis, become inactive bone-lining cells, 
or become embedded within the bone matrix as osteocytes. The molecular mechanisms 
determining OB fate are not well understood, however. While all the physiological roles of 
osteocytes are still being elucidated, it is known that osteocytes secrete fibroblast growth factor-
23 (FGF23), which acts on the kidney to regulate serum phosphorous levels and may also be 
important to bone formation induced by mechanical loading (42-44). The lack of a specific 
molecular marker to distinguish osteocytes from OBs, however, has precluded the successful 
generation of osteocyte-specific genetic models. 
Part II. Osteoclast signaling pathways 
 As stated above, OCs arise from hematopoietic precursors in the bone marrow (45). The 
cytokines M-CSF and RANKL are required for precursor survival, proliferation, and 
commitment to the OC lineage. Exposure to M-CSF first pushes the cells to the myeloid lineage. 
While the exact OC precursor in vivo is unknown, several groups have characterized myeloid 
cells with high osteoclastogenic potential with the surface markers CD11b–/loCD115+CD117+ 
(46, 47). Further stimulation of these cells with the cytokine RANKL commits them to the OC 
lineage. During the early phases of osteoclastogenesis, the cells exit the cell cycle and cease 
dividing, at which point they will become terminally differentiated OC  (48). 
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M-CSF signaling 
M-CSF, encoded by the gene Csf1, is produced by OBs in both a membrane and soluble 
form. The necessity of M-CSF specifically in the context of the OC and bone is underscored by 
the severe osteopetrotic phenotype of op/op mice which harbor a mutation in Csf1. Op/op mice 
fail to develop OC in vivo, leading to extremely high bone mass and impaired tooth eruption 
(49).  Dai and colleagues also deleted the receptor for M-CSF, c-fms, and found a similar 
impairment in OC differentiation and bone resorption in vivo (50). 
 c-Fms is a receptor tyrosine kinase which undergoes dimerization and 
autophosphorylation following ligation to M-CSF. This autophosphorylation of tyrosine residues 
in the cytoplasmic tail provides a docking site for the SH2 motif of Src family kinases, namely c-
Src. This signaling at the receptor activates 2 major intracellular signaling pathways: PI3K and 
MAPK (51, 52). PI3K is recruited directly to the receptor and activates downstream protein 
kinase B (Akt), which in turn stimulates gene transcription for cell proliferation via cyclin 
proteins. Akt also signals to mTOR to promote anti-apoptotic pathways and cell survival. The 
MAPK pathway induces extracellular related kinase (ERK) activation, which turns on the 
cascade of activation leading to p38, c-Jun, and JNK2 phosphorylation. This pathway is 
ultimately necessary to induce the transcription factor Mitf that turns on the anti-apoptotic 
protein Bcl-2 (53). In fact, overexpression of Bcl-2 is sufficient to rescue the high bone mass 
phenotype of the op/op mice (54).  Through these pathways, M-CSF is indispensable to support 
the survival and proliferation of OC precursors, and importantly, also up-regulates their 
expression of RANK.  
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RANKL signaling 
 RANKL is a member of the TNF superfamily that is wholly necessary for OC 
differentiation. Mice lacking RANKL or its receptor RANK present with a complete lack of OCs 
and failure in tooth eruption (12, 55). RANKL exists as both membrane-bound form, such as it is 
found on OB and perhaps osteocytes, and also in secreted form following cleavage by ADAM (a 
disintegrin and metalloprotease domain) and matrix metalloproteases (56, 57). Secreted RANKL 
is produced by T cells in the inflamed synovium and appears to contribute significantly to joint 
destruction during rheumatoid arthritis (58). The majority of RANKL is present in the 
membrane-bound form, however, and thus osteoclastogenesis requires direct cell-to-cell contact.  
 The binding of RANKL monomers to the receptor RANK, a TNF superfamily member, 
induces receptor trimerization. Downstream signaling is dependent on protein scaffolding at the 
receptors’ cytoplasmic tail, which harbors no intrinsic enzymatic activity of its own. RANK can 
recruit several isoforms of the TNF-related factor (TRAF) family of adaptor proteins (59). Of 
these, TRAF6 is particularly important, as TRAF6-null mice present with high bone mass owing 
to defective OC differentiation (60). A second adaptor, Gab2, also appears to be critical in 
protein scaffolding at RANK, as Gab2-/- mice also suffer from osteopetrosis (61-63). The 
assembly of these molecules initiates downstream signaling of MAPK and NF-kB pathways that 
modulate both OC differentiation as well as bone resorption (Figure 1.3).  
NF-kB  
 The family of NF-kB transcription factors, comprised of p50, p52, p65 (also known was 
RelA), RelB, and c-Rel, can be activated via 2 distinct pathways referred to as the classical and 
alternative pathways (64, 65). Both classical and alternative NF-kB are activated by RANKL 
signaling (Figure 1.4). In the classical pathway, the IKK kinase complex, composed of IKK,, 
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and , is activated by TRAF6, and in turn phosphorylates IKB66). In steady-state conditions, 
IKB functions to retain the NF-kB family member p50 in the cytoplasm in complex with p65 or 
cRel. Phosphorylation of IKB targets the protein for proteosomal degradation, allowing the 
release and nuclear translocation of the p50-p65/cRel dimer and activation of NF-kB responsive 
genes. On the other hand, the alternative pathway is dependent on the kinase NIK, which in 
steady state conditions is rapidly degraded via TRAF3-mediated ubiquitination. Recruitment of 
TRAF3 to RANK, however, allows for NIK stabilization and its activation of the IKK complex. 
IKK in turn activates the processing of p100 to the active form p52 (66, 67). RelB pairs with 
p52, and the dimer can then translocate to the nucleus and activate gene transcription.  
 Mice deficient in both p50 and p52 and thus totally lacking NF-kB signaling present with 
osteopetrosis due to lack of OC differentiation (68, 69). RelA knockout mice have significantly 
fewer OC in basal conditions due to increased apoptosis and are protected from inflammatory 
osteolysis (70).  Similarly, RelB-/- mice fail to form OC when challenged with TNF- in vivo, 
and RelB-/- precursors cannot undergo osteoclastogenesis in vitro (71).  Thus, both the classical 
and alternative pathways are necessary for OC differentiation and function. While induction of 
the classical pathway occurs very rapidly and transiently within minutes of RANKL stimulation, 
the alternative pathway is turned on slowly over the course of hours and is sustained. Likewise, 
classical and alternative NF-kB signaling appear to regulate different processes during 
osteoclastogenesis. Classical NF-kB promotes OC precursor survival while alternative signaling 
contributes to differentiation.  
cFos/AP-1  
 In addition to NF-kB, the transcriptional complex AP-1 is also essential to OC formation 
(Figure 1.5). During osteoclastogenesis, it appears that multiple signaling pathways synergize to 
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activate AP-1 induction, including NF-kB, calcium activation of CREB, and the MAP kinase 
component p38 (72, 73). Among the members of the AP-1 family, c-Fos is most important to the 
OC, as evidenced by the severe high bone mass and lack of OCs in the c-Fos -/- mouse (74). It is 
unclear why c-Fos is specifically important in the OC compared to other AP-1 proteins including 
Fra-1, JunB, or c-Jun, and which genes are uniquely targeted by c-Fos for osteoclastogenesis 
(75). Interestingly, it has recently been observed that c-Fos induction during osteoclastogenesis is 
more strongly dependent on M-CSF signaling compared to RANKL signaling cascades, and this 
pathway appears to be dependent on PLC-mediated generation of diacylglycerol (Zamani et al., 
in press).  
Co-stimulatory receptors in osteoclastogenesis 
  The OC is wholly dependent on ongoing intracellular Ca2+ fluxes to induce and support 
differentiation. While Ca2+ fluxes during osteoclastogenesis are known to be compulsory to 
differentiation and function, these signals are not actually originated by RANK directly. It was 
previously known that in immune cells, phospholipase C gamma (PLC) generates Ca2+ fluxes 
downstream of co-stimulatory molecules (76). In the OC, co-stimulatory receptors are associated 
with adapter molecules, namely DAP12 and FcR, containing an Immunoreceptor tyrosine-based 
activation motif (ITAM) which enables downstream signaling (77).  
 In the OC, DAP12 and FcRare ITAM-containing adaptors which appear to be essential 
to osteoclastogenesis. While the deletion of either of these genes alone does not result in a 
significant bone phenotype, double knock out mice present with severe osteopetrosis, suggesting 
that these co-stimulatory pathways may compensate for one another in vivo (78-81). ITAM-
containing proteins do not bind ligand themselves but are coupled to receptors. In the OC, 
DAP12 couples to TREM2, TREM3, SIRb1, and MDL-1. Interestingly, patients with mutations 
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in either TREM2 or DAP12 suffer from recurring fractures and osteolytic lesions (82). Similarly, 
TREM2-/- mice show low bone mass due to accelerated OC formation in the face of 
dysregulated -catenin (83). These studies suggest that TREM2 may be the most important co-
stimulatory molecule in humans. The ligand for TREM2 is not yet known. On the other hand, 
FcR associates with the receptor OSCAR, which has recently been shown to bind collagen in 
the matrix . 
During osteoclastogenesis, signaling at RANK cross-talks with the ITAM-containing 
adaptors to initiate downstream PLC-dependent signaling cascades (Figure 1.6). In the OC 
specifically, two Src family kinases, c-Src and Fyn, which are recruited to RANK, first 
phosphorylate the tyrosine residues of the ITAM domain. Deletion of c-Src results in 
cytoskeletal defects in the OC but not impaired differentiation, however, so it is currently unclear 
which Src-family kinases can activate ITAM signaling in the OC to modulate osteoclastogenesis. 
Following phosphorylation of the ITAM, the kinase Syk is recruited via its SH2 domain. 
Similarly to the phenotype of c-Src knock out cells, deletion of Syk disrupts the OC cytoskeleton 
but does not abrogate differentiation, suggesting that other kinases may be able carry out this 
step. Syk activation recruits the scaffolding proteins BLNK and SLP76, and this signalosome 
complex leads to eventual phosphorylation of PLC, turning on its catalytic activity.  
As active lipases, PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into the 
second messengers inositol-3-phophate (IP3) and diacylglycerol (DAG). Through these 
pathways, PLC activates downstream Ca2+ fluxes and DAG-dependent signaling effectors 
including PKCs, respectively (85). There are two isoforms of PLC: PLC1 which is 
ubiquitously expressed and PLC2 which is expressed only in hematopoietic lineages. While 
PLC1-/- mice do not survive, PLC2-deficient mice are viable (86). These mice are 
12 
 
characterized by a severe osteopetrotic phenotype owing to defective OC differentiation. 
Surprisingly, although PLC1 is intact in these mice, PLC1 cannot compensate for the loss of 
PLC2. In vitro experiments revealed that impaired osteoclastogenesis in the absence of PLC2 
is due to defective NFATc1 upregulation (87). Interestingly, overexpression of NFATc1 in 
PLC2-/- cells can rescue OC formation but not bone resorption (88). Further studies showed 
that DAG signaling to PKCd downstream of PLCg2 regulates Cathepsin K-containing vesicle 
secretion. DAG remains at the membrane and can activate multiple downstream effectors, 
including protein kinase C- delta (PKC) in the OC. This DAG-PKC pathway regulates 
secretion of Cathepsin K-containing vesicles in the mature OC (28).  
Ca2+  fluxes in osteoclastogenesis 
 The OC is wholly dependent on sustained intracellular Ca2+ fluxes for differentiation 
(Figure 1.7). RANKL-induced activation of PLC2 leads to the generation of IP3, which diffuses 
through the cytosol and binds the IP3 receptor (IP3R) on the ER membrane. IP3Rs multimerize 
to form a Ca2+ channel, allowing release of Ca2+ from ER stores (89). In the OC, it appears that 
IP3R isoforms 1, 2, and 3 are expressed. The osteopetrotic phenotype of IP3R2/3 doubly 
deficient-mice suggest that these isoforms may be most important Ca2+ fluxes in the OC, 
however (90). Stim1 is an ER Ca2+ sensor that harbors an EF-hand Ca2+ -binding domain. When 
Ca2+ levels decline in the ER, Ca2+ is dissociated from Stim1, inducing a conformational change 
and its translocation within to ER-plasma membrane junctions (91-95). Here, Stim1 binds to and 
activates the protein Orai1 (96). Orai1 is the pore-forming subunit of the Ca2+ release activated 
Ca2+ (CRAC) channel. Extracellular Ca2+ enters the cell’s cytoplasm through the CRAC channel 
(97-99). ER Ca2+ stores are replenished via active transport of Ca2+ by the Sarco-endoplasmic 
reticulum Ca2+ ATPase (100, 101). Through these mechanisms, intracellular Ca2+ fluxes are 
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sustained in the OC. Genetic deletion of Orai1 or SERCA2, as well as pharmacological 
inhibition of Stim1, each abolish Ca2+ fluxes and OC differentiation (101-103).  
Nfatc1 as the OC master transcription factor  
 Following RANKL stimulation, NF-kB, AP-1, and Ca2+ signaling pathways all contribute 
to the induction of NFATc1, a member of the family of NFAT transcription factors. NFAT 
proteins are sequestered in the cytosol in basal conditions due to masking of their nuclear 
localization sequence. De-phosphorylation by the calcium-dependent phosphatase calcineurin 
results in a conformational change to allow NFAT nuclear translocation (104). Within the 
nucleus, NFAT is also regulated by phosphorylation by a number of kinases including GSK3 
(105, 106). This phosphorylation induces NFAT nuclear export to the cytosol. Interestingly, 
NFATc1 can also bind to its own promoter to auto-amplify its transcription and protein 
expression (107).  
 The importance of NFATs during osteoclastogenesis is evidenced by both 
pharmacological and genetic studies. Cyclosporin A, an inhibitor of calcineurin and therefore 
NFAT, strongly suppresses osteoclastogenesis in vitro.  Although NFATc1-/- mice are 
embryonic lethal, NFATc1-null embryonic stem cells are unable to undergo osteoclastogenesis 
(108). More recently, conditional deletion of NFATc1 via Mx1-cre was demonstrated to increase 
bone mass in mice by inhibiting OC formation (109).  NFATc1 has been deemed the “master 
transcription factor” of osteoclastogenesis, as it directly regulates OC-specific genes including 
TRAP, calcitonin receptor, Cathepsin K, and 3 integrin (107, 110, 111). 
NFATc1 is regulated by several transcriptional repressors that control its activation. 
Interferon regulator factor-8 (IRF8) and Bcl6 are constitutively bound to the NFATc1 promoter, 
and their expression is down-regulated within 24 hours of RANKL stimulation (112-115). 
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Interestingly, Bcl6 is down-regulated via the RANKL-dependent induction of its repressor 
Blimp1 (114). Thus, RANKL-induced alleviation of transcriptional repression allows robust 
NFATc1 activation and auto-amplification.   
Part III. Osteo-immune activation in arthritis 
During pathological bone loss as occurs in arthritic conditions, both the bone and immune 
cells are activated. This osteo-immune cross-talk has become increasingly recognized as a driver 
of debilitating joint erosion. Both the innate and adaptive immune cells participate in this osteo-
immune activation. In the state of an inflammatory trigger, innate immune cells, namely 
neutrophils, mast cells, and macrophages, are rapidly recruited to the joint. Importantly, multiple 
signaling pathways, including NF-kB, MAPK, and PLC2/Ca2+/NFAT, are shared in the 
response of both bone and immune cells and both to inflammatory cytokines (116).  
Inflammatory cytokines fuel bone loss  
Arthritic patients show high levels of inflammatory cytokines both in circulation and 
locally in the joint. TNF- and IL-1 in particular upregulate RANKL expression by OBs and 
stromal cells, thereby increasing osteoclastogenesis (57, 117, 118). Moreover, these cytokines 
can also act directly on the OC precursor and synergize with RANKL to amplify OC 
differentiation (119-122). Both anti-TNF and IL-1 receptor antagonist are used as treatments in 
arthritic conditions, although not all patients are responsive to cytokine inhibition. The cytokine 
IL-17, produced by Th17 cells, is also believed to be pathogenic in psoriatic arthritis by 
increasing the production of RANKL by T cells and B cells (123).   
 The role of IL-6 and IFN-during pathological bone loss is less clear. IL-6 deficient mice 
show no OC phenotype in basal conditions but are protected from ovariectomy-induced bone 
less (124, 125). Similarly, increased IL-6 levels have been observed in post-menoposal women, 
15 
 
suggesting that this cytokine may specifically contribute to estrogen-deficient bone loss (126). 
The role of IFN- in bone is also unclear. In mice but not humans, IFN- inhibits 
osteoclastogenesis in vivo in arthritic conditions (127). However, IFN- positively regulates 
macrophage activation and consequent inflammatory cytokine production (128), and therefore 
could indirectly increase osteoclastogenesis. 
Immune cells in bone 
 Both adaptive and innate immune responses contribute to a pro-resorptive environment in 
the joint space. Adaptive immune responses by T cells and B cells through the recognition of 
specific auto-antigens and production of auto-antibodies can also contribute to uncontrolled 
immune responses. T cells produce IFN- which amplifies the innate pro-inflammatory response 
as well as antigen presentation (129). Additionally, T cells can secrete RANKL to activate OCs 
(130). B cells also have more recently been proposed to produce RANKL themselves (131, 132). 
Through these pathways, the immune response fuels OC over-activity and also amplifies the 
innate immune response, allowing progressive joint destruction.  
 Innate immune cells, including neutrophils, mast cells, and monocytes/macrophages, are 
the first cells to infiltrate the joint during arthritic conditions. Through the production of 
inflammatory cytokines, reactive oxygen species, and release of proteolytic granules, these cells 
induce local tissue damage, recruit more immune cells to the joint, and activate 
osteoclastogenesis (133). Unlike the adaptive immune cells, which edit their receptors to 
recognize specific antigens and can develop immunological memory, the innate response is 
dependent on fixed pattern recognition receptors (PRRs) which are fixed to identify discreet 
pathogen- associated molecular patterns (PAMPs) and elicit a rapid response, as well as Fc 
receptors which bind the Fc fragment of antibodies. In the context of inflammatory bone loss, 
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innate immune cells are activated via Toll-like receptor (TLR) ligands (including bacterial, viral, 
and fungal components as well as endogenous TLR ligands), complement deposition, and 
immune complex formation(134-136). In animal models of inflammatory arthritis, the depletion 
or inhibition of neutrophils or macrophages alone is sufficient to protect the joint from 
infiltrating leukocytes and bone loss, underscoring the importance of these cells types in arthritic 
disease (137-139). Natural killer (NK) cells are innate cytotoxic cells that are capable of directly 
killing infected cells by the release of granules containing perforin and proteases.  NK cells are 
found in the synovial fluid of rheumatoid arthritis patients and also express both M-CSF and 
RANKL, thereby supporting osteoclastogenesis from monocytes in the joint (140)  Lastly, 
dendritic cells (DCs) are the bridge between the innate and adaptive response. DCs take up 
antigen in the periphery and then migrate to the lymph nodes where they present antigen to T-
cells, thus activating an antigen-specific response (141). DCs are present in the synovial fluid of 
RA patients where they appear to promote T cell-inflammatory responses, and DC migration and 
antigen presentation are wholly required in animal models of antigen-induced arthritis (142, 
143). While much more work is ongoing to understand the contribution of each of these cell 
types to arthritic diseases, this thesis will focus on the monocyte/macrophage lineage for both its 
direct contribution to the OC lineage and pro-inflammatory functions.  
 Macrophage development and function 
 Tissue-resident macrophages are professional antigen presenting cells which maintain 
homeostasis in physiological conditions, rapidly respond to an immunological challenge, and 
mediate tissue repair and restoration. From the hematopoietic stem cell (HSC), there are 4 known 
intermediates leading to macrophage differentiation: common myeloid progenitors (CMP), 
granulocyte and macrophage progenitors (GMP), macrophage and dendritic cell progenitors 
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(MDP), and finally the common monocyte progenitors (CMoP). Bone marrow and splenic red 
pulp macrophages are believed to actually be established before birth and are independently 
maintained. On the other hand, splenic marginal zone macrophages are continually renewed by 
differentiating monocytes in circulation (144). In the context of arthritis, synovial macrophages 
and inflammatory monocytes are derived from the circulating population, whose numbers are 
increased in arthritic patients (145). 
 In tissues, macrophages are highly phagocytic cells that are on watch to engulf foreign 
material, cellular debris, as well as microbial and viral particles. The engulfed material is housed 
in a phagosome which fuses with a lysosome of low pH, allowing digestion in the 
phagolysosome. Through this pathway, macrophages are highly efficient at clearing unwanted 
matter from the tissue to prevent or control an infection before the adaptive immune response is 
mounted. As professional APCs, macrophages also express both MHC Class I and Class II 
molecules to present endocytosed and processed antigen to CD8+ and CD4+ T cells, 
respectively, thus stimulating a specific adaptive immune response (144, 146).  
 Macrophages can further dictate the immune response by producing a number of 
cytokines, both pro- and anti-inflammatory. In the past, macrophages were segregated into M1 
and M2 subtypes, reflecting their contributing roles to T helper cell 1 and T-helper cell 2 
responses, respectively. In these classifications, M1 macrophages are generated by exposure to 
IFN-g in combination with the bacterial cell wall component lipopolysaccharide (LPS) or TNF. 
M1 macrophages are strongly pro-inflammatory and anti-tumorigenic through the production of 
IL-1, TNF, IL-6, and iNOS, as well as enhanced MHC Class II antigen presentation capacity. On 
the other hand, M2 macrophages result from stimulation with some combination of IL-4, IL-13, 
or IL-10. Stimulation with these cytokines upregulates production of arginase and IL-10 and 
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increases expression of the scavenger receptor CD206. These M2 macrophages participate in 
allergic and anti-parasitic responses, immunoregulation, and perhaps tumor promotion (146).  
 Macrophages in rheumatic disease 
 
Monocyte and macrophage numbers are elevated in arthritic patients and can contribute 
to disease both through their inflammatory actions and their differentiation into bona fide bone-
resorbing OCs. One model disease in which this monocyte/macrophage population is playing an 
essential yet enigmatic role is systemic juvenile idiopathic arthritis (sJIA). sJIA is an episodic 
auto-inflammatory disease that, unlike other arthritic subtypes, is primarily driven by innate 
immune cells. Expanded monocyte numbers, particularly during episodes of disease flare, are 
observed in sJIA patients. The trigger of this excessive monocyte response is unknown. These 
monocytes may be activated by an infectious stimuli or endogenous TLR ligands inducing a pro-
inflammatory response. Intriguingly, M2-like monocytes appear during episodes of disease flare 
and persist into the transition to a quiescent state, suggesting that this M2 population arises in an 
attempt to ameliorate the systemic inflammatory environment (147-151). In fact, it is still 
unknown whether the excessive pro-inflammatory response or defective anti-inflammatory 
response truly underlies the pathologies of sJIA. Thus, a better understanding of the signaling 
pathways which modulate the plasticity of the monocyte/macrophage lineage and potentiate a 
switch to an anti-inflammatory response would be highly applicable to sJIA, in addition to 
numerous macrophage-mediated pathologies.  
Approximately 10% of sJIA patients develop macrophage activation syndrome (MAS), 
which is responsible for the majority of the morbidities associated with sJIA.  The onset of MAS 
is sudden, and patients present with high fever, hepatosplenomegaly, lymphadenopathy, 
cutaneous and mucosal bleeding, pancytopenia, as well as central nervous system, cardiac, and 
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renal involvement. Patients have very high levels of inflammatory cytokines, TNF-, IL-1, IL-6, 
IL-18, as well as IFN- in the serum. Importantly, MAS is so-named due to a massive influx of 
activated macrophages in the bone marrow, liver and spleen. It is actually unknown if this 
increase in macrophages is driving pathogenesis or is an attempt to control a dysregulated 
adaptive immune response (152). The sJIA/MAS field is currently lacking a clear picture of how 
the activated monocyte/macrophage population functions at both a cellular and molecular level 
during the onset and course of disease.   
Part IV. PLC2 as an osteo-immune modulator 
PLC structure and function 
PLC is a 150kDa protein containing both an active lipase domain as well as several 
scaffolding motifs to facilitate protein interactions. The catalytic domain is split into 2 hemi 
domains that are separated and thus non-functional in the resting state. PLCphosphorylation 
downstream of receptor activation induces a conformational change to bring together the split 
catalytic domain. The scaffolding domains of PLC include tandem SH2 domains, an N-terminal 
PH domain, a split PH domain, and an SH3 domain. The split PH domain comes together in 
PLC’s active conformation, but its exact role is unknown. The N-terminal PH domain is 
responsible for PLC membrane and substrate targeting by binding directly to PIP2. The tandem 
SH2 domains appear to be necessary for protein scaffolding at the receptor complex by binding 
to phosphorylated tyrosine motifs, while the SH3 domain recognizes the conserved PxxP motif 
on binding partners. Finally PLC also harbors a C2 calcium-binding domain at its C-terminus 
which also participates in membrane binding (85).  
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PLC Signaling in Osteo-Immunology 
In order to better target both the overactive immune and OC responses underlying 
inflammatory osteolysis and arthritis, it is necessary to identify common signaling components 
shared by these systems. PLC2 is such a critical mediator of the osteoimmune system owing to 
its requirement to both innate immune response and OC formation and function. PLC2-/- mice 
are osteopetrotic due to a defect in both OC formation as well as function (28, 87). Interestingly, 
both the enzymatic and scaffolding functions of PLC2 play distinct yet essential roles in 
promoting osteoclastogenesis (87). While PLC2’s catalytic activity is necessary to stimulate 
Ca2+ fluxes leading to NFATc1 activation, its scaffolding domains are required for NF-kB and 
AP1 induction.  
In addition to a pronounced bone phenotype, PLC2-/- mice exhibit defects in neutrophil, 
macrophage, dendritic cell, and NK cell responses. More specifically, PLC2 deletion prevents 
the induction of IL-1, TNF-, and IL-6 by macrophages stimulated by TLR2 and TLR4 ligands 
(153, 154). Importantly, PLC2-/- mice are protected from inflammatory cytokine production in 
the K/BXN serum transfer model of arthritis, specifically due to impaired inflammatory cytokine 
expression (155). While PLC2 seems an appealing therapeutic target, its extensive homology 
with other PLC isoforms presents a challenge for specific targeting in vivo. Therefore, we must 
focus on developing novel methods to therapeutically target PLC2 and its downstream signaling 
pathways. In this thesis, I demonstrate a novel method of targeting PLC2 via its unique SH2 
domains to protect from osteolysis. In chapters 3 and 4, I describe a novel PLC2-dependent 
protein, Tmem178, and its surprising role in the regulation of inflammatory bone loss and 
macrophage activation. 
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     1.2 Figures 
 
 
  Figure 1.1 Osteoclast differentiation from myeloid precursors 
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Figure 1.2 Osteoclast-osteoblast coupling in bone remodeling 
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Figure 1.3 Protein scaffolding at RANK initiates NF-kB and MAPK cascades 
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Figure 1.4 Classical and alternative NF-kB pathways 
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Figure 1.5 RANK activates MAPK signaling to induce cFos and the AP1 
transcriptional complex 
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Figure 1.6 RANK cross-talks with ITAM-coupled receptors to activate PLC2 
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Figure 1.7 PLC2 activates ER Ca2+ release coupled to Ca2+ entry, leading to 
cytosolic Ca2+ fluxes driving NFATc1 activation 
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2.2 Abstract 
Phospholipase C gamma β (PLCȖβ) is a critical regulator of innate immune cells and 
osteoclasts (OCs) during inflammatory arthritis. Both the catalytic domain and the adaptor motifs 
of PLCȖβ are required for OC formation and function. Due to the high homology between the 
catalytic domains of PLCȖβ and the ubiquitously expressed PLCȖ1, molecules encompassing the 
adaptor motifs of PLCȖβ were designed to test the hypothesis that uncoupling the adaptor and 
catalytic functions of PLCȖβ could specifically inhibit osteoclastogenesis (OCG) and bone 
erosion.  Wild-type (WT) bone-marrow macrophages (BMM) that over-express the tandem SH2 
domains of PLCȖβ (SHβ(N+C)) failed to form mature OCs and resorb bone in vitro.  Activation 
of the receptor activator of NF-κB (RANK) signaling pathway, which is critical for OC 
development, was impaired in cells expressing SH2(N+C).  Arrest in OC differentiation was 
evidenced by a reduction of p38 and Iκ-Bα phosphorylation as well as decreased NFATc1 and 
cFos/cJun levels.  Consistent with our hypothesis, SH2(N+C) abrogated formation of the 
RANK/Gab2 complex which mediates NF-κB and AP-1 activation following RANK ligand 
(RANKL) stimulation. Furthermore, the ability of SH2(N+C)  to prevent  inflammatory 
osteolysis was examined in vivo following RANKL or LPS injections over the calvaria. Both 
models induced osteolysis in the control group, whereas the SH2(N+C)-treated cohort was 
largely protected from bone erosion.  Collectively, these data indicate that inflammatory 
osteolysis can be abrogated by treatment with a molecule composed of the tandem SH2 domains 
of PLCȖβ. 
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2.3 Introduction 
Pathological bone loss is a debilitating complication associated with prosthetic implants, 
osteoarthritis, rheumatoid arthritis, and periodontal disease (1) and results from an increase in the 
number and/or function of the bone-resorbing OC (2).  OCs are differentiated from BMM 
precursors in the presence of RANKL and macrophage colony-stimulating factor (M-CSF), 
which bind RANK and c-Fms, respectively (3).  Pro-inflammatory cytokines TNF-α, IL-1ȕ, and 
IL-6, which are produced at inflamed joints, further promote OCG and resorptive activity (4).  
Such crosstalk between immune cells and OCs highlights the need for a therapeutic treatment 
capable of reducing inflammation and preventing bone erosion.   
 PLC1 and 2 molecules are critical regulators of innate and adaptive immune 
responses and are activated during OC differentiation.  These enzymes convert 
phosphatidylinositol 4,5 bisphosphate (PIP2) into two second messengers, inositol 1,4,5-
triphosphate (IP3) and diacylglycerol (DAG), leading to activation of IP3/calcium and DAG-
dependent pathways downstream of RANK, integrins, and a variety of immune receptors (5). For 
example, in vitro studies of T lymphocytes demonstrate that PLCȖ1 is a critical modulator of T 
cell receptor responses (6-8).  However, PLCȖ1 is ubiquitously expressed, and its global deletion 
leads to early embryonic lethality in the mouse (9).  Thus, an approach to inhibit PLCȖ1 function 
is likely to have broad off-target effects. PLCȖβ expression is confined to cells of hematopoietic 
lineage, including B lymphocytes, natural killer cells, mast cells, neutrophils, dendritic cells, and 
OCs (10-14). PlcȖβ-/- mice have increased bone mass (osteopetrosis) due to reduced 
differentiation of BMMs into OCs (15). Additionally, PlcȖβ-/- mice are protected from serum-
transfer induced arthritis and antigen-induced arthritis due to functional defects in neutrophils 
and dendritic cells, respectively (13,14). Therefore, PLC2 is a promising target for therapeutic 
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design in the context of inflammatory osteolysis.  However, due to its high homology with the 
more ubiquitously expressed PLCȖ1, it is necessary to find inhibitors which can selectively block 
PLCȖβ activation. 
 PLCȖ1 and PLCȖβ are unique from other PLC molecules because they contain 
two tandem SH2 and an SH3 adaptor motifs. Initial studies suggested that these adaptor motifs 
harbor an intrinsic regulatory function of the protein’s catalytic activity (16), exposing the 
catalytic domain upon PLCȖ1/β phosphorylation (17).  However, it is now established that these 
SH2 and SH3 motifs can also mediate protein-protein binding via homodomain interactions (17).  
Considering that the catalytic domains of PLCȖ1 and PLCȖβ are over 90% homologous, while 
their adaptor motifs are less than 60% homologous, the latter regions are a potential target for 
specific inhibition.  
 The scaffolding function of PLCȖβ, in addition to its catalytic activity, is required 
for OC formation.  Cells with a point mutation in the SHβ domain of PLCȖβ are incapable of in 
vitro OCG despite intact catalytic function (18). Thus, we hypothesized that the scaffolding 
function of endogenous PLCȖβ could be disrupted through a dominant negative effect by a 
molecule encompassing the adaptor domains of PLCȖβ.  We report that a molecule composed of 
the tandem SH2 motifs of PLC2 is able to abrogate OCG in vitro and in vivo by disrupting 
protein interactions between RANK and Gab2. This approach may represent a novel method of 
targeting PLC2 to prevent inflammatory bone loss.  
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2.4 Materials and Methods 
Plasmids and retrovirus generation  
The SHβ or SHγ domains of PLCȖβ were cloned into the blasticidin-resistant pMX retroviral 
vector and fused with HA.  To generate retrovirus, PLAT-E cells were transfected with 
expression vector by using a TransIT transfection reagent (Mirus Bio).  Viral supernatants were 
collected on day 2 and day 3 post-transfection and immediately used to transduce freshly isolated 
BMMs. After β4 h, medium containing 1 μg/ml blasticidin was added to cells for 48 h to select 
for expressing cells.  
Primary cell culture 
Bone marrow was isolated from long bones of 6- to 8-week-old C57BL/6 mice and cultured in 
alpha-MEM containing 10% heat-inactivated fetal bovine serum, 100 IU/ml penicillin, and 100 
μg/ml streptomycin, and glutamine (α-10 medium), with 1/10 vol CMG14-12 cell-conditioned 
medium as a source of macrophage colony-stimulating factor (M-CSF) (19) to obtain BMMs.  
To form OCs, BMMs were cultured in α-10 medium with 100  ng/mL glutathione S-transferase–
receptor activator of NF-κB ligand (GST-RANKL) and 1/100 vol CMG14-12 for 5 days. Cells 
were fixed in 4% paraformaldehyde and stained for tartrate-resistant acid phosphatase (TRAP) 
using a commercial kit (Sigma 387-A). 
Real-time PCR 
 BMMs were cultured with 100  ng/mL RANKL and 1/100 vol CMG14-12  for 0, 2, or 4 days.  
Adherent cells were harvested in Trizol.  Total RNA was isolated by chloroform extraction 
followed by purification with the RNeasy Mini Kit (Qiagen).  1 μg of total RNA was reverse 
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transcribed to cDNA using SuperScript II according to the manufacturer’s instructions 
(Invitrogen).  For real-time PCR, SYBR Green PCR Master Mix (Applied Biosystems) and 
primers specific for murine NFATc1, TRAP, cathepsin K, calcitonin receptor, and GAPDH, 
were used as follows:  NFATc1, 5′-CCCGTCACATTCTGGTCCAT-γ′ and 5′-
CAAGTAACCGTGTAGCTGCACAA-γ′; TRAP, 5′-CAGCTCCCTAGAAGATGGATTCAT-γ′ 
and 5′-GTCAGGAGTGGGAGCCATATG-γ′; cathepsin K, 5′-
ATGTGGGTGTTCAAGTTTCTGC-γ′ and 5′-CCACAAGATTCTGGGGACTC-γ′; calcitonin 
receptor, 5′-CAAGAACCTTAGCTGCCAGAG-γ′ and 5′-CAAGCACGCGGACAATGTTG-γ′; 
GAPDH 5′-TGTGTCCGTCGTGGATCTGA-γ′and  5′-CCTGCTTCACCACCTTCTTGA -γ′).  
Ct values were normalized to GAPDH internal control.  Data are expressed as the relative fold 
change compared to the expression in BMMs transduced with pMX empty vector control at day 
0. 
Bone Resorption 
 Analysis of bone resorption was completed as described previously (18). Briefly, BMMs were 
plated on bovine bone slices and cultured with 1/100 CMG14-12  and 100 ng/ml GST-RANKL 
for 10 days.  Fresh medium was added every 2 days. Cells were removed from the bone surface 
by using mechanical force and β N NaOH. Bone slices were stained with β0 μg/ml peroxidase-
conjugated wheat germ agglutinin for γ0 min (Sigma) followed by γ,γ′-diaminobenzidine (0.52 
mg/ml in PBS containing 0.1% H2O2) for 15 min. Bone resorption pits were visualized with a 
light microscope and quantified using Image J software (NIH; http://rsbweb.nih.gov/ij). 
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Immunoprecipitation 
Cells were harvested in lysis buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM 
EDTA, 10% glycerol) supplemented with protease inhibitors, and clarified by centrifugation. 
The protein concentration of each sample was determined using bicinchoninic acid protein assay 
(Biorad) and 1 mg of protein from each sample was used for IP. Samples were incubated with 
anti-PLCȖβ (Santa Cruz Biotechnology) or anti-Gab2 antibody (Millipore) overnight at 4°C and 
with protein G agarose beads (Amersham) for 3 h at 4°C. Beads were washed three times in lysis 
buffer and immunoprecipitates were used for western blotting. 
RANKL, M-CSF, and vitronectin stimulation 
 For RANKL and M-CSF stimulation, pre-OCs were starved for 4 hours in α-MEM containing 
2% FBS and then stimulated with RANKL (100 ng/ml) or M-CSF (100 ng/ml) in α-MEM for the 
indicated times.  Cells were lysed in radioimmunoprecipitation assay (RIPA) lysis buffer 
supplemented with HALT protease and phosphatase inhibitor cocktail (Pierce). To obtain nuclear 
extracts from RANKL-treated cells, tissue-culture plates were washed with H2O and the 
adherent cells were lysed with hypotonic buffer (10 mM HEPES, 1.5 mM MgCl2, 1 mM KCl, 1 
mM DTT, and protease and phosphatase inhibitors), followed by addition of 0.1% NP40. After 
centrifugation, the supernatants were collected (cytosolic fraction), while the pellets (nuclear 
fraction) were suspended in high-salt buffer (hypotonic buffer plus 400 mM NaCl).  For 
vitronectin stimulation, pre-OCs were washed with PBS and lifted with 10% trypsin/EDTA in 
PBS.  Cells were replated on tissue-culture plates coated with vitronectin for the indicated length 
of time and lysed in RIPA lysis buffer supplemented HALT protease and phosphatase inhibitor 
cocktail. 
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Western blot analysis and antibodies 
The protein concentration of cell lysates or nuclear extracts was determined using bicinchoninic 
acid protein assay (Biorad). An equivalent amount of protein for each sample was mixed with 5x 
loading buffer (312.5mM Tris pH 6.8, 10% SDS, 50% glycerol, 0.05% bromophenol blue, 10% 
-mercaptoethanol), separated by SDS-PAGE and transferred to PVDF membranes.  Membranes 
were probed with antibodies as indicated.  Antibodies specific to the phosphorylated forms of 
PLCȖ1, PLCȖβ, ERK, JNK, c-Jun, IκBα, and Src (Y416) were purchased from Cell Signaling 
Technology.  Antibodies against p65, NFATc1, PLCȖβ, TRAF6, RANK, Lamin B, and Sp1 were 
purchased from Santa Cruz Biotechnology.  The monoclonal antibody against ȕ-actin was 
purchased from Sigma-Aldrich.  Polyclonal Gab2 Ab was purchased from Millipore. 
In vivo osteolysis models 
 WT C57Bl/6 mice were treated with 100 μg of RANKL and 107 PFU of adenovirus containing 
LacZ (Ad-LacZ control) or SH2(N+C) (Ad-SH2(N+C)) by subcutaneous injections over the 
calvaria daily for 5 days.  Mice were sacrificed on day 6 and the calvaria were collected for 
histological analysis.  The calvaria were preserved in 10% buffered formalin overnight 24 h and 
decalcified with 14% EDTA for 4 days.  Paraffin-embedded sections were stained for tartrate-
resistant acid phosphatase (TRAP) to visualize OCs. WT C57Bl/6 mice were treated with γ0 μg 
LPS and 107 PFU of adenovirus containing Ad-LacZ or Ad-SH2(N+C) by subcutaneous 
injections over the calvaria at day 0, followed by 107 PFU of Ad-LacZ or Ad-SH2(N+C) on day 
1, 3, and 5.  Mice were sacrificed on day 6, and the calvaria were processed for histological 
analysis as described above.  Paraffin-embedded sections were stained for TRAP to visualize 
OCs (Sigma).  
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All mice used in these experiments were housed in the animal care unit of Washington 
University School of Medicine, where they were maintained according to guidelines of the 
Association for Assessment and Accreditation of Laboratory Animal Care. All animal 
experimentation was approved by the Animal Studies Committee of Washington University 
School of Medicine. 
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2.5 Results 
SH2(N+C) blocks OCG in vitro 
To design an efficient strategy to specifically oppose endogenous PLCȖβ activity in the 
context of pathological bone loss, we focused on the protein modular domains, as the catalytic 
motif is highly homologous to PLC1. Retroviral constructs harboring the N- and C-terminal 
SH2 domains alone or in combination (N+C), the SH3 domain, or encompassing both SH2 and 
SH3 regions were generated (Figure 2.1 A).  These constructs were transduced into WT BMMs 
that also express endogenous PLCȖβ.  Expression of the indicated domains was confirmed by 
western blot (Figure 2.1 B).  BMMs were treated with RANKL and M-CSF, and differentiation 
to mature OCs was evaluated by TRAP staining. RANKL and M-CSF induced differentiation of 
precursor cells into OCs in all groups, except in the presence of the SH2(N+C) and partially in 
SH2(N+C)+SH3 expressing cells.  Ectopic expression of SH2(N+C) significantly impaired OC 
development (# of TRAP+ cells in SH2(N+C), 1.3±0.88 versus empty vector, 153.3±8.99, p < 
0.0001).  A 52% inhibition of OCG was observed in WT cells expressing SH2(N+C)+SH3, 
while the differentiation of cells expressing a single SH2 (either SH2-N or SH2-C) or the SH3 
motif alone was similar to cells infected with the empty vector (pMX; Figure 2.1 C-D). 
Consistent with its inhibitory effect on OC formation, BMMs that were transduced with 
SH2(N+C) and grown on cow bone slices in the presence of RANKL and M-CSF for 7 days, 
formed fewer resorptive pits compared to pMX-transduced controls (Figure 2.2).  
To further understand which stage of OC differentiation was blocked by the expression of 
SH2(N+C), real time PCR was used to quantify expression of the early osteoclastogenic marker 
TRAP and the master transcription regulator of OCG NFATc1, the functional OC protease 
cathepsin K, and the calcitonin receptor expressed by mature OCs (Figure 2.3). WT cells 
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transduced with empty vector alone showed an upregulation for all conventional markers of 
OCG during four days of culture in the presence of RANKL and M-CSF.  In contrast, expression 
of OC differentiation markers was dramatically reduced in WT cells expressing SH2(N+C), 
indicating that this molecule targets signaling pathways involved early in the OC differentiation 
process. 
RANK signaling cascade is inhibited by SH2(N+C) in vitro 
In order to understand how SH2(N+C) inhibits OCG in vitro, we analyzed activation of 
signaling pathways downstream of RANK/RANKL stimulation, M-CSF/c-Fms stimulation, or 
vitronectin/alpha-v beta-γ (αVȕγ) integrin ligation. WT day β pre-OCs expressing SH2(N+C) or 
vector control were stimulated with 100ng/ml RANKL for 0 to 60 minutes, as indicated.  Pre-
OCs expressing SH2(N+C) failed to activate downstream RANK signals, as assayed by Western 
blot for phosphorylation of PLCβ, IKBα and pγ8 and upregulation of cFos and NFATc1 (Figure 
4A). Activation of JNK was unaffected (not shown). Furthermore, nuclear translocation of 
NFATc1 and phosphorylated c-Jun was inhibited by SH2(N+C) expression (Figure 4B).  In 
contrast, when pre-OCs were stimulated with 100ng/ml of M-CSF over the indicated time 
course, cells expressing SH2(N+C) induced phosphorylation of the downstream molecules AKT 
and ERK equivalent to cells expressing the vector alone (Figure 2.4 C).  Phosphorylation of 
Pyk2, c-Src, and IkB was decreased in SH2(N+C)-expressing pre-OCs plated on vitronectin 
(Figure 4D). All together, these results indicate that SH2(N+C) primarily inhibits the RANKL- 
and integrin-mediated signaling pathways which are integral to OC differentiation. 
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SH2(N+C) blocks association of Gab2 with PLC2 and RANK 
 In order to understand the mechanism by which SH2(N+C) interferes with the RANKL 
signaling cascade, a co-immunopreciptation assay of cell lysates from RANKL-stimulated pre-
OCs was preformed. Following RANKL binding to its receptor RANK, the signaling adaptor 
Gabβ is recruited to the RANK complex (β0). Gabβ associates with PLCȖβ to stimulate 
phosphorylation of Iκ-Bα leading to OCG (15,20). SH2(N+C) dampened the association of 
PLCȖβ with Gabβ compared to pre-OC expressing vector only (Figure 2.5 A).  Furthermore, 
SH2(N+C) also impaired the association of RANK with Gab2 but did not effect recruitment of 
TRAF6 to Gab2 (Figure 2.5 B). Thus, SH2(N+C) inhibits RANK signaling cascades by 
impeding protein scaffolding at the receptor. 
SH2(N+C)blocks OC formation in vivo 
 Finally, the potential efficacy of targeting PLC2 adaptor motifs to inhibit bone erosion 
was examined in vivo, using two established models of OCG.  To facilitate these studies, 
adenoviral vectors were generated to express SH2(N+C) or beta galactosidase (LacZ) as a 
control.  LacZ expression after one intra-articular injection of 107 PFU was confirmed by X-gal 
staining (data not shown).  In the first model, 100 μg of RANKL and 107 PFU of Ad-SH2(N+C) 
or Ad-LacZ were administered to WT mice by subcutaneous injections over the calvaria daily for 
5 days.  Mice were sacrificed on day 6, and calvaria were prepared for histological examination 
to assess the number of TRAP+ OCs.  WT mice receiving SH2(N+C) adenovirus displayed 
significantly fewer OCs compared to LacZ-expressing controls (Figure 2.6 A). Furthermore, the 
effect of SH2(N+C) in the context of inflammatory bone loss was examined using an established 
model of OCG initiated by a single LPS injection over the calvaria.  γ0 μg of LPS and 107 PFU 
55 
 
of SH2(N+C) or control LacZ adenovirus were injected over the calvaria at day 0, followed by 
107 PFU of SH2(N+C) or control LacZ adenovirus every other day for five days. Mice were 
sacrificed on day 6, and calvaria were examined by histology. WT mice receiving SH2(N+C) 
adenovirus developed half the number of TRAP-positive OC compared to LacZ-expressing 
controls (Figure 6B). These results indicate that PLC2 can be specifically targeted in vivo by a 
dominant-negative effect of the SH2(N+C), and that this approach can abrogate inflammatory-
induced OC formation.  
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2.6 Discussion 
Inhibitors that block the catalytic activity of PLC proteins, such as ET-18-OCH3 and 
U73122, have been used to establish the function of PLCs and the importance of PIP2 hydrolysis 
into IP3 and DAG in various cellular contexts. However, the major limitation of these inhibitors 
is lack of specificity.  Using a genetic model consisting of PlcȖβ-deficient mice, we previously 
showed that PLCȖβ is required for the maintenance of basal bone mass and for protection from 
inflammatory arthritis (13-15). Thus, the goal of the current study was to identify a specific 
approach to target endogenous PLCȖβ function. We report that ectopic expression of the tandem 
SHβ domains of PLCȖβ phenocopies the intrinsic OC deficit of PlcȖβ-/- mice (15) by disrupting 
the protein association between RANK and Gab2. This approach is a novel method of targeting 
endogenous PLCȖ2 function to negate pathological bone loss.  
PLCȖβ is important for both OC differentiation and bone resorption.  We previously 
proposed that in the context of OCG, PLC2 serves a dual purpose as both an active lipase, 
leading to expression of the master osteoclastogenic transcription factor NFATc1, and as a 
critical scaffolding molecule facilitating NF-κB and AP-1 induction.  Point mutations in the SH2 
domains of PLCȖβ (R564K/R67βK) render BMMs unable to differentiate to OCs, despite intact 
catalytic activity (18). Here, we show that the overall effect of the SH2(N+C) was inhibition of 
the RANK signaling cascade and suppression of OCG.  Our observations support an independent 
scaffolding function of PLCȖβ in which the SHβ motifs of PLCȖβ mediate the association 
between RANK and Gab2.  Our results suggest that ectopic expression of SH2(N+C) exerts a 
dominant negative effect on formation of this complex by sequestering Gab2 and thus impairing 
its binding to the receptor RANK. These observations are consistent with modeling of 
intracellular RANK receptor interactions (21,22).  During the first hour of RANKL stimulation 
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(early activation phase), PLCȖβ is recruited to RANK, and Gab2 binds weakly to the recruited 
PLCȖβ without interacting directly with RANK (β1).  Following prolonged RANKL stimulation 
(beyond 24 h) Gab2 may bind to the HCR region of RANK and recruit TRAF6 (21,22).  Thus, it 
is hypothesized that the scaffolding function of PLCȖβ is critical in the early phase, whereas its 
catalytic activity may modulate signaling during the early and late phases of RANKL stimulation 
(21,22).  Importantly, concurrent exposure to the SH2(N+C) and RANKL can limit OCG in vitro 
and in vivo. 
Gab2 belongs to a family of adaptor molecules that mediate signals downstream of a 
diverse set of receptors for molecules such as growth factors, antigens, cytokines, TLR agonists, 
and the RANK receptor.  Gab2-deficient mice exhibit impaired OCG and a net increase in bone 
mass.  Gab2 is also necessary for the differentiation of human progenitor cells into OCs (20).  In 
vitro, BMMs from Gab2-deficient mice do not form mature OCs due to an inherent defect that 
correlates with reduced RANKL-mediated activation of NF-kB, Akt, and JNK. Similarly, ectopic 
expression of SH2 (N+C) primarily affects RANKL signaling in OCs, without altering 
downstream signals from the MCSF receptor, thus implying a good level of specificity for this 
type of targeted approach. Since a Gabβ/PLCȖβ complex is likely to form in response to various 
stimuli, inhibitory effects of the SH2(N+C) in other contexts are possible and warrant further 
investigation. 
In contrast to the SH2(N+C), the anti-osteoclastic effects of molecules encompassing 
each single SHβ domain or the entire adaptor motif of PLCȖβ, consisting of the two SHβ 
domains along with the SH3 motif, were very minimal.  It is likely that targeting only one SH2 
domain is not sufficient to sequester adaptor molecules from forming a complex with RANK. 
However, it was surprising to find that a larger fragment encompassing the entire adaptor region 
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of PLCȖβ had less effect than the SHβ(N+C) molecule. Initial models of PLCȖ1, and perhaps 
PLCȖβ, function suggested that, at the 3D structural level, the entire adaptor region 
(SH2(N+C)+SH3) forms a cap that regulates exposure of the catalytic domain to its substrate 
(17).  Indeed, overexpression of SH2(N+C)+SH3 was shown to block phospholipase activity of 
cell lysates in vitro (16).  Similarly, this region exerted a dominant-negative effect to reduce 
PLCȖ1 enzyme activity in prostate tumor cells and resulted in reduced tumor invasiveness (βγ).  
While previous reports clearly demonstrate that the entire adaptor region modulates catalytic 
activity, they do not clarify whether or not this region also mediates protein-protein binding.  In 
the OCs, the incomplete inhibition of OCG by SH2(N+C)+SH3 supports the hypothesis that 
SHβ(N+C)+SHγ is not fully capable of blocking PLCȖβ catalytic activity.  
 SH2(N+C) anti-osteoclastogenic effects are also observed in vivo using two 
models of bone loss, consisting of RANKL or LPS supracalvarial injections. While RANKL 
directly stimulates the differentiation of monocytes into OCs, LPS-induced bone loss is 
secondary to immune activation. In vivo immune phenotypes caused by genetic alterations of 
PlcȖβ have been described.  We and others have shown that PLCȖβ regulates inflammation and 
autoimmunity, specifically within the bone microenvironment.  PlcȖβ-/- mice are protected from 
immune activation in serum-transfer arthritis and antigen-induced arthritis (13,14).  In humans, a 
dominantly-inherited disease called PLAID (PLCȖβ-associated antibody deficiency and immune 
dysregulation) is caused by mutant alleles of PLCȖβ in which small, in-frame genomic deletions 
eliminate part or all of the C-terminal SHβ domain of PLCȖβ.  Immune cells from these patients 
displayed functional deregulation, with increased activation in response to some stimuli and 
decreased activation in other circumstances (12). Although we did not directly test the effects of 
SH2(N+C) on immune cell activation or function, it is possible that SH2(N+C) may also 
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modulate inflammatory responses involved in LPS-mediated bone loss in addition to directly 
targeting the OCs. Further studies are needed to examine potential anti-inflammatory effects of 
SHβ(N+C). In conclusion, the results reported here provide strong evidence that PLCȖβ adaptor 
function can be targeted in vitro and in vivo to suppress OCG and bone erosion. 
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2.8 Figure Legends 
FIGURE 2.1. SH2(N+C) blocks OC formation in vitro. 
A, Schematic representation of the functional domains of the PLCȖβ protein and the regions of 
the protein present in retrovirus constructs.  B, Western blot analysis was used to confirm 
expression of the indicated domains of PLCȖβ by detection of the HA tag.  C-D, WT BMMs 
were transduced with retrovirus to express the indicated peptides and cultured under 
osteoclastogenic conditions.  Cells were fixed and stained to detect TRAP+ cells.  C, 
Quantification of the TRAP+ cells per well.  D, Representative bright-field micrographs. 
FIGURE 2.2 SH2(N+C) blocks bone resorption.   
WT BMMs were transduced with pMX empty vector or -SH2(N+C) and cultured on tissue 
culture plastic, A, or cow bone slices, B, in the presence of 100 ng/mL RANKL and 10 ng/mL 
M-CSF.  A, Representative images of cells stained with TRAP.  B, Representative images of 
cow bone slices stained with wheat germ agglutinin to visualize areas of resorbed bone.  C, The 
surface area of resorbed bone was quantified as percent of total bone surface area. 
FIGURE 2.3. SH2(N+C) regulates the expression of osteoclastogenic genes. 
WT BMMs expressing pMX empty vector control or SH2(N+C) were cultured in the presence of 
100 ng/mL RANKL and 10 ng/mL M-CSF.  Relative expression of the OC-specific markers 
TRAP, cathepsin K (CatK), calcitonin receptor (CTR), and NFATc1 were detected by real-time 
PCR.  Ct values were normalized to GAPDH and are represented as fold change compared to 
pMX control at day 0. 
FIGURE 2.4. SH2(N+C) suppresses RANK signaling. 
WT BMMs were transduced with pMX empty vector or SH2(N+C) in the presence of 100 
ng/mL RANKL and 10 ng/mL M-CSF prior to starvation and stimulation.  A-B, Pre-OCs were 
stimulated with 100 ng/mL RANKL for 0 – 60 minutes, as indicated.  Whole cell lysates (A) and 
nuclear extracts (B) were separated by SDS-PAGE and western blots were probed with the 
indicated antibodies.  Total Pyk2, actin, or Lamin B are shown as loading controls. C, Pre-OCs 
were stimulated with 50 ng/mL M-CSF for 0 – 30 minutes, as indicated, and analyzed as in A.  
D, Pre-OCs were lifted and replated on plates coated with vitronectin for 0 – 60 minutes, as 
indicated, and analyzed as in A. 
FIGURE 2.5. SH2(N+C) disrupts binding of Gab2 with PLC2 and RANK. 
WT BMMs were transduced with pMX empty vector or SH2(N+C) and cultured in the presence 
of 100 ng/mL RANKL and 10 ng/mL M-CSF prior to starvation and stimulation.  Pre-OCs were 
stimulated with 100 ng/mL RANKL for 0 – 60 minutes, as indicated.  1 mg of protein from 
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whole cell lysates were immunoprecipitated with anti-PLCȖβ, A, or anti-Gab2 antibody, B, and 
then separated by SDS-PAGE.  Western blots were probed with antibodies as indicated.  
FIGURE 2.6. SH2(N+C) inhibits OC formation in vivo.  
A, WT C57Bl/6 mice were treated with 100 μg RANKL and 107 PFU of Ad-LacZ or Ad-
SH2(N+C) by supracalvarial injection daily for 5 days.  Mice were sacrificed on day 6 and the 
calvaria were collected for histological analysis.  Representative images of histological sections 
stained to detect TRAP+ OCs (red cells) and quantification of the percent quantification of OC 
surface per bone surface (Oc.S./B.S.) and OC number per bone surface (Oc.N./B.S.).  B, WT 
C57Bl/6 mice were treated with γ0 μg LPS and 107 PFU of Ad-LacZ or Ad-SH2(N+C) by 
supracalvarial injection at day 0 followed by Ad-LacZ or Ad-SH2(N+C) every other day.  Mice 
were sacrificed on day 6 and the calvaria were collected for histological analysis.  Representative 
images of histological sections stained to detect TRAP+ OCs and quantification of OC surface 
per bone surface (Oc.S./B.S.) and OC number per bone surface (Oc.N./B.S.) are shown.  
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Chapter 3. The Role of Tmem178 in the Regulation of Osteoclastogenesis 
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3.2 Abstract 
PLC2-dependent calcium (Ca2+) oscillations are indispensable for NFATc1 activation 
and downstream gene transcription driving osteoclastogenesis during skeletal remodeling and 
pathological bone loss. Here we describe the first known function of transmembrane protein 178 
(Tmem178), a PLC2 downstream target gene, as a critical modulator of the Ca2+-NFATc1 axis. 
In surprising contrast to the osteopetrotic phenotype of PLC2-/- mice, Tmem178-/- mice are 
osteopenic in basal conditions and are more susceptible to inflammatory bone loss, owing to 
enhanced osteoclast formation. Mechanistically, Tmem178 localizes to the ER membrane and 
restrains ER Ca2+ release, thus controlling NFATc1 induction. Importantly, downregulation of 
Tmem178 is observed in human CD14+ monocytes exposed to plasma from systemic juvenile 
idiopathic arthritis patients. Similarly to the mouse model, reduced Tmem178 expression in 
human cells correlates with excessive osteoclastogenesis.  In sum, these findings identify an 
essential role for Tmem178 to maintain skeletal mass and limit pathological bone loss.  
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3.3 Introduction 
In recent years, the skeleton has been appreciated as a dynamic system which, in addition 
to serving its evident mechanical functions, impacts whole-body metabolism. The bone is a 
reservoir for mineral stores, namely calcium (Ca2+) and phosphate, and also releases and 
responds to numerous growth factors and hormones. Through these pathways, skeletal turnover 
stimulates cross-talk with the nervous, endocrine, immune, reproductive, and digestive systems. 
Skeletal fragility is observed in inflammatory, endocrine, and metabolic disorders [1, 2]. Perhaps 
the most studied inflammatory condition associated with dysregulated bone homeostasis is 
rheumatoid arthritis (RA). Elevated levels of inflammatory cytokines acting in concert with the 
receptor activator of NF-kB ligand (RANKL) drive excessive osteoclast (OC) differentiation and 
lead to local joint erosion as well as systemic bone loss [3, 4]. Pathological bone loss was also 
observed in up to 50% of patients with systemic juvenile idiopathic arthritis (sJIA) before the 
pre-biological era. However, even in the face of optimal anti-inflammatory therapy, joint damage 
is still observed in up to 20% of children without active systemic features (Janow et al., 
manuscript submitted). Furthermore, low bone mass and high risk of fragility fracture are often 
seen in adults who suffered from sJIA during childhood [5]. Unfortunately, at the moment there 
are no biomarkers of specific factors that would help identify which subset of patients will 
develop active erosive disease or long term osteopenia.  
Ca2+ is a ubiquitous signaling messenger directing diverse processes such as 
differentiation, proliferation, migration, and gene transcription. Ca2+ fluxes are particularly 
important during the OC differentiation process as a rise in cytoplasmic Ca2+ triggers the 
Ca2+/calmodulin-dependent nuclear translocation of NFATc1, a master transcription factor for 
osteoclastogenesis [6-8]. Ca2+ signaling is initiated by binding of RANKL to its receptor RANK 
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inducing the activation of PLC2-mediated release of ER Ca2+ stores through IP3 receptors 
(IP3R). Upon detecting depletion of ER Ca2+, Stim1, an ER Ca2+ sensor, binds to Orai1, a pore-
forming unit of the CRAC (Ca2+ release activated Ca2+) channel, and allows extracellular Ca2+ 
entry through the plasma membrane [9-19]. Ca2+ entry from the extracellular milieu in the OC 
can also occur via transient receptor potential V channels [20-22]. ER Ca2+ is re-filled by the 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) [23]. Genetic or pharmacological 
interference of Ca2+ channel activity, as well as blockade of PLC2-mediated Ca2+ release, 
impedes osteoclastogenesis, cell motility, and bone resorption in vitro and in vivo [24-29]. 
Because of its importance to many cellular responses, Ca2+ mobilization is finely 
controlled by regulatory proteins that potentiate or suppress Ca2+ transport and dictate amplitude, 
duration, and/or frequency of Ca2+ fluxes. Several interacting partners of Stim1 and Orai1 have 
been identified as regulators of CRAC channel activity. Interestingly, emerging data also indicate 
that Stim1 and Orai1 can interact with regulatory proteins to exert non-CRAC channel-related 
functions [30, 31]. Such interacting proteins remain unknown in the context of the OC.  
In this study we identify for the first time a previously uncharacterized protein, Tmem178, as a 
novel modulator of ER Ca2+ mobilization in OCs. Our data demonstrate that Tmem178 is a 
negative regulator of OC differentiation by limiting ER Ca2+ release and activation of the Ca2+-
dependent osteoclastogenic transcription factor NFATc1. In mice, Tmem178 deficiency leads to 
a significant osteopenic bone phenotype owing to increased OC numbers. Human monocytes 
treated with plasma from sJIA patients downregulate Tmem178 and undergo more robust 
osteoclastogenesis, suggesting that Tmem178 may be a modulator of disease-associated bone 
erosion.  
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3.4 Materials and Methods 
Mice  
PLC2-/- mice were kindly provided by Dr. JN Ihle (St. Jude Children’s Research Hospital, 
Memphis, Tennessee, USA). Tmem178-/- mice (Strain B6;129S5-Tmem178tm1Lex/Mmucd) 
were generated by the trans-NIH Knock-Out Mouse Project (KOMP) and purchased from the 
KOMP Repository at UC Davis (www.komp.org) (stock number 032664-UCD). Tmem178 bone 
phenotyping was performed with mice of the C57Bl/6-129 background maintained by 
heterozygous breeding. In vitro osteoclast experiments were performed with bone marrow from 
both mice of C57Bl/6-129 and C57Bl/6 background. All experiments were approved by the 
Washington University School of Medicine animal care and use committee.  
Histology and µCT  
Microcomputed tomography and histological analysis were performed as previously 
described [53].For histology to detect OCs, bones were preserved in 10% buffered formalin 
overnight and decalcified using 14% EDTA, pH 7.0, for 10 days (long bones) or 3 days 
(calvaria) with gentle rocking and daily replacement of solution. Decalcified bones were then 
dehydrated in graded alcohol, cleared through xylene, and embedded in paraffin. Paraffin blocks 
were sectioned longitudinally. Five-micron sections were then stained with TRAP (Sigma) to 
detect OCs and counterstained with hematoxylin. For double-labeling, 4 week-old WT and 
Tmem178-/- mice were injected with calcein and alizarin red at a 4 day interval. Calvaria were 
harvested on day 5, stored in 70% ethanol and protected from light. Five-micron sections were 
analyzed from non- decalcified, methacrylamide embedded calvaria. Sections were analyzed 
with a Nikon Eclipse 80i microscope and a 10X objective. For μCT, 3D images from intact 
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mouse femurs or calvaria were obtained on a μCT40 scanner (Scanco Medical). For LPS-
induced osteolysis on the calvaria, resorbed area was quantified using Image J Software. 
Inflammatory osteolysis models 
For serum-transfer arthritis, 200 l of serum from K/BxN mice was injected i.p. into recipient 
mice on day 0, day 2 and day 6. 50 g of Lipopolysaccharides (LPS) from Escherichia coli 
0111:B4 (Sigma) was injected on day 6. Mice were sacrificed on day 14, and long bones were 
harvested for analysis by CT and histology. For surpacalvarial LPS, 100 g LPS was injected 
subcutaneously over the calvaria on day 0. Mice were sacrificed on day 5, and calvaria were 
harvested for analysis by CT and histology. 
Primary cell culture 
BMMs were isolated from 6-8 week old mice as previously described [54].  Briefly, the marrow 
of long bones was flushed by centrifugation and isolated cells were grown in alpha medium 
(Sigma) in the presence of 100 ng/ml M-CSF for 3 days. To form OCs, BMMs were cultured 
with 50 ng/ml glutathione-S-transferase (GST)-RANKL and 10 ng/ml M-CSF for 3-5 days. Cells 
were fixed in 4% paraformaldehyde (Polysciences) and stained for TRAP using the leukocyte 
acid phosphatase kit (Sigma).  
Bone resorption  
5 × 104 BMMs or preOCs were cultured on bovine bone slices the presence of 10ng/ml M-CSF 
and 50ng/ml GST-RANKL. Cells were then removed from the bone surface using sodium 
hydroxide and gentle agitation, and bone slices were stained with 20 µg/ml peroxidase-
conjugated wheat-germ agglutinin (Sigma) for 30 min at room temperature, followed by 
incubation with 3,3'-diaminobenzidine (0.52 mg/ml in PBS containing 0.1% H2O2) for 30 min.  
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Bone resorption pits were analyzed using a light microscope (Nikon) and quantified using Image 
J software.  
Western blot and antibodies  
For RANKL and M-CSF signaling assays, BMMs were starved overnight in cytokine- 
and serum-free alpha medium; preOCs were starved for 4 hours in cytokine-free alpha medium 
containing 2% FBS. For total cell lysates, BMMs or preOCs were lysed in RIPA buffer 
supplemented with protease/phosphatase inhibitor cocktail (Pierce). For nuclear extracts, cells 
lysed with hypotonic buffer (10 mM HEPES, 1.5 mM MgCl2, 1 mM KCl, 1 mM DTT, and 
protease and phosphatase inhibitors), followed by addition of 0.1% NP40. After centrifugation, 
the supernatants were collected (cytosolic fraction), while the pellets (nuclear fraction) were 
suspended in high-salt buffer (hypotonic buffer plus 400 mM NaCl). For immunoprecipitation, 
cells were harvested in TNE lysis buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM 
EDTA, 10% glycerol). Protein concentration was determined by bicinchoninic acid protein assay 
(Biorad), resolved by SDS-page and subjected to western blot analysis 
For immunoblotting and immunoprecipitation, phospho-ERK (D13.14.4E), phospho-JNK 
(81E11), phospho-p38 (3D7), phospho-IκBα (14D4), phospho-AKT (587F11), Myc (9B11), 
Pyk2 (3292), and Lamin B1 (13435) antibodies were obtained from Cell Signaling Technology. 
NFATc1 (7A6) was purchased from Santa Cruz, as well as secondary anti-mouse and anti-rabbit 
HRP-conjugated antibodies. Mouse monoclonal HA.11 (16B12) was purchased from Covance. 
Flag-M2 and beta-actin were purchased from Sigma. Protein A/G beads were obtained from 
Santa Cruz. 
Real-time PCR  
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Cells were lysed in TRIzol (Invitrogen), and whole tissues were snap frozen in liquid nitrogen 
then pulverized with a dismembrator (B. Braun Biotech International) in TRIzol. Total RNA was 
isolated using the RNeasy Mini Kit (Qiagen) and reverse transcribed to cDNAs using EcoDry 
Premix (Oligo dT) (Clontech). For quantitative real-time PCR, NFATc1 was amplified using 5′-
CCCGTCACATTCTGGTCCAT-3′ and 5′-CAAGTAACCGTGTAGCTGCACAA-3′.TRAP was 
amplified using 5′-CAGCTCCCTAGAAGATGGATTCAT-3′ and 5′-
GTCAGGAGTGGGAGCCATATG-3′; cathepsin K using 5′-
ATGTGGGTGTTCAAGTTTCTGC-3′ and 5′-CCACAAGATTCTGGGGACTC-3′; calcitonin 
receptor using 5′-CAAGAACCTTAGCTGCCAGAG-3′ and 5′-
CAAGCACGCGGACAATGTTG-3′; and cyclophilin using 5’- 
AGCATACAGGTCCTGGCATC-3’ and 5’-TTCACCTTCCCAAAGACCAC-3’. Tmem178 in 
mouse cells was amplified using 5’-ATGACAGGGATATTTTGCACCAT-3’ and 5’-
CCGGTTCAAGTCATAGGAGACACT-3’and in human cells using 5’- 
ACTTATGCCGCCAGTATCTCG-3’ and 5’- AGGCGCAAAAGATGGACCAG-3’. For 
measuring transcriptional repressors, Bcl 6 was detected using 5’-TTA GAG CCC ATA AGA 
CAG TGC T-3’ and 5’-TCA GGT TGA GCC TAG ATG TGT-3’; IRF8 using 5’-AAG GTC 
ACC GTG GTC CTT AG-3’ and 5’-GGA AAG CCT TAC CTG CTG AC-3’. SYBR green dye 
was used for detection of the product using the SYBR Green PCR Master Mix assay (Applied 
Biosystems). The standard curve used a series of duplicate dilutions of plasmid for each gene and 
cyclophilin cDNA. The amplification reaction was performed for 40 cycles with denaturation at 
95°C for 10 minutes, followed by annealing at 95°C for 15 seconds and extension and detection 
at 60°C for 1 minute. The relative abundance of each target was calculated as 1000×2−(Ct target 
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gene−Ct cyclophilin), where Ct represents the threshold cycle for each transcript, and cyclophilin is the 
reference. 
Plasmids and retrovirus generation 
Human Tmem178 cDNA (Clone ID 528607- Open Biosystems) was cloned into the blasticidin-
resistant pMX retroviral vector containing an HA tag at the C-terminus using BamHI and XhoI 
restriction sites. Stim1-Myc and Orai1-Flag were a gift from Dr. Monika Vig (Washington 
University). 
To generate retrovirus, PLAT-E cells were transfected with expression vector using PolyJet 
transfection reagent (SignaGen). Viral supernatants were collected on day 2 post-transfection and 
immediately used to infect freshly isolated BMMs with the addition of 4 ug/ml polybrene. After 
24 h, complete medium containing 1 μg/ml blasticidin was added to cells for 48 h to select for 
expressing cells. Selected cells were differentiated to OC with 10 ng/ml M-CSF and 50 ng/ml 
RANKL in the presence of 0.3 ug/ml blasticidin.  For expression studies in HEK293T cells, 
Tmem178-HA, Stim1-Myc-His, or Orai1-Flag were co-transfected into HEK293T cells using 
PolyJet. Transfected cells were used for Ca2+ imaging or lysed for immunoprecipitation 
experiments 24 hours later.  
Immunofluorescence and microscopy  
OCs were differentiated on glass coverslips with 10 ng/ml M-CSF and 50 ng/ml RANKL. Cells 
were fixed with 4% paraformaldehyde (Polysciences) for 10 minutes then rinsed 3 times with 
PBS. Cells were permeabilized with 0.2% Triton for 10 minutes, and blocked in 3% BSA-1% 
FBS for 30 minutes. Primary antibody diluted in PBS supplemented with 3% BSA and 0.1% 
saponin was added for 2 hours at room temperature, followed by 2 hours incubation with 
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secondary antibody (1:500) together with phalloidin-Alexa Flour 488 (1:500) (Molecular 
Probes). The following antibodies and dilutions were used: Calnexin (C20) purchased from 
Santa Cruz (1:50), c-myc (9E10) from Santa Cruz (1:50), HA (HA-7) from Sigma (1:2000), HA-
FITC (Ab1208) purchased from Abcam (1:100), anti-goat Alexa Fluor 594 (1:500), anti-mouse 
Alexa Fluor 594 (1:500), and anti-mouse Alexa Fluor 488 (1:100). Vectashield containing dapi 
nuclear stain was purchased from Vector Labs. Slides were analyzed using a Nikon Eclipse 80i 
microscope and a 63X Plan APO objective. Images were captured with a Nikon DS-Qi1MC 
camera (Nikon). For confocal images, slides were analyzed using a Zeiss Axiovert 200M 
microscope and Zeiss LSM 5 PASCAL system.  
Single cell Ca2+ measurements 
For Ca2+ measurements, cells were seeded in a black 96-well plate. BMMs were seeded at a 
concentration of 12,000 cells/well for 1 day with 10 ng/ml M-CSF and 50 ng/ml RANKL. Cells 
were loaded with 3 M Fura-2-AM (Invitrogen) in phenol red-free DMEM (Invitrogen) 
containing 10 ng/ml M-CSF for 30 minutes at room temperature in the dark. Cells were washed 
twice with HBSS and imaged immediately in phenol red-free DMEM containing 10 ng/ml M-
CSF. Cells were imaged for 1 minute before the addition of 100 ng/ml GST-RANKL. For preOC 
treated with thapsigargin or ionomycin, cells were imaged in Ca2+-HBSS. For experiments using 
HEK293T cells, 24 hours post-transfection cells were plated at a concentration of 15,000 
cells/well for 4 hours on poly lysine-coated wells. Cells were loaded with 3 -2-AM in 
HBSS for 30 minutes at 37°C. Cells were washed twice in HBSS and imaged immediately in 
Ca2+-free HBSS. Fura-2 ratios were measured by alternate excitation at 340 nm and 380 nm. An 
Olympus IX-71 inverted microscope with a Lamda-LS illuminator,  Fura-2 (340/380) filter set, a 
10X 0.3NA objective lens, and a Photometrics Coolsnap HQ2 CCD camera was used to capture 
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images at a frequency of 1 image pair every 2 seconds. Data were acquired and analyzed using 
MetaFluor. At least 40 cells per field were analyzed in each replicate. 
Human plasma preparation 
The study was approved by the Institutional Review Board at Stanford University. All subjects 
provided informed consent before participating in the study in accordance with the Declaration 
of Helsinki. Plasma was prepared from whole, anti-coagulated blood within 2 hours after blood 
draw. Samples were centrifuged at 25°C at 514 g for 5 minutes to remove cells, and were 
centrifuged for 2 additional rounds at 4°C at 1730 g for 5 minutes and 15 minutes to remove 
platelets. Plasma samples were stored at -80°C until use.  
Human osteoclastogenesis 
PBMCs were isolated from healthy donor by Ficoll gradient centrifugation. CD14+ cells were 
isolated by positive selection with anti-CD14 magnetic beads (Miltenyi Biotec). For 
osteoclastogenesis, 600,000 CD14+ PBMCs were seeded in a 96-well plate with 30 ng/ml human 
M-CSF.  After 24 hours, media was added to a final concentration of 15 ng/ml human M-CSF 
and 100 ng/ml GST-RANKL. At 48 hours and 96 hours, the total media was changed. The 
complete media included 15 ng/ml hM-CSF, 100 ng/ml GST-RANKL, and 15% plasma by 
volume (25 l in 200 l total volume). For Tmem178 mRNA analysis, CD14+ PBMCs were 
cultured with hM-CSF and GST-RANKL for 48 hours. 15% control or patient plasma was added 
for 8 hours.  
Statistics  
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All data represent mean ± SD. Data were analyzed using two-tailed Student’s t test, with 
a P value of <0.05 set as statistically significant. *p<0.05 **p<0.01, ***p<0.001 
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3.5 Results 
Tmem178 deletion decreases bone mass in basal conditions 
We have previously reported that ablation of PLC2 results in a blockade of 
osteoclastogenesis owing to defective NFATc1 induction in vitro and in vivo [32, 33]. PLC2 -
deficient mice are osteopetrotic and are also protected from inflammatory osteolysis [34, 35]. 
Because PLC2 shares significant homology with the more ubiquitously expressed isoform 
PLC1, however, attempts at pharmacological inhibition of PLC2 are likely to have broad off-
target effects. Therefore, we sought to identify PLC2-dependent signaling mediators that could 
specifically direct therapeutic design for disorders caused by OC overactivity such as 
osteoporosis and rheumatoid arthritis. We performed a gene array comparing wild-type (WT) 
and PLC2-deficient OC precursors to identify novel genes downstream of PLC2 signaling. 
Transmembrane protein 178 (Tmem178) was highly expressed in WT cells, but Tmem178 
expression was abrogated in cells lacking PLC2 (data not shown).    
Tmem178 is a previously unstudied multi-pass integral membrane protein. Despite its 
name, Tmem178 does not share any structural domains or homology with other “Tmem” 
proteins. We began by assessing Tmem178 expression in whole tissues from WT and PLC2-/- 
mice. Strikingly, we found that Tmem178 is highly expressed in WT whole bone, while 
transcript levels are low in other tissues including, spleen, liver, thymus, and testes (Figure 3.1 
A). Confirming the gene array data, Tmem178 expression was strongly dependent on PLC2. 
Thus, we hypothesized that Tmem178 is a downstream target controlling PLC2’s effects on 
bone homeostasis.  
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To establish the physiological importance of Tmem178 we examined the bone phenotype 
of Tmem178-null mice in basal conditions. We expected Tmem178-/- mice to mirror the 
osteopetrotic phenotype of PLC2-/- mice. Surprisingly, 16 week-old female Tmem178-/- mice 
display a 35% decrease in trabecular bone volume with significant trabecular thinning compared 
to WT littermates (Figure 3.1 B-D).  Tartrate-resistant acid phosphatase (TRAP) staining of long 
bone sections reveals a significant increase in OC surface normalized to bone surface in 
Tmem178-/- mice (Figure 3.1 E-F). Similarly, male Tmem178-/- mice show a 10% decrease in 
BV/TV compared to WT controls, with concomitant increase in OC surface/bone surface (n = 4-
5) (data not shown). Because OC-mediated bone resorption is coupled to OB activity, we 
performed double labeling in 4 week-old mice by administering calcein and alizarin red at a 5 
day interval.  WT and Tmem178-/- mice show no significant differences in mineral apposition 
rate (MAR) and bone formation rate (BFR) (Figure 3.1 G-I). Moreover, quantitative real time 
PCR of whole bones flushed of marrow cells reveals equal expression of RANKL and OPG in 
WT and Tmem178-/- mice (Figure 3.1 J-K). Thus, the basal osteopenic phenotype of Tmem178-
/- mice can be attributed to an OC-intrinsic effect. These in vivo data suggest that Tmem178 acts 
to suppress OC differentiation via an unexpected negative feedback loop downstream of PLC2.  
Tmem178 expression is controlled by NFATc1 
To determine whether Tmem178 exerts cell autonomous effects in the OC lineage, we 
measured its transcript levels during osteoclastogenesis in vitro. Tmem178 mRNA increases 
during osteoclastogenesis and is dependent on PLC2 (Figure 3.2 A-B). A similar extent of 
Tmem178 induction is observed in human CD14+ monocytes treated with RANKL compared to 
cells cultured with M-CSF alone (Figure 3.2 C). In contrast to the OC, Tmem178 is not 
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significantly expressed in the OB, confirming the observation that Tmem178 deletion does not 
affect bone formation (Figure 3.2 A).  
PLC2’s catalytic activity is required for induction of NFATc1 early in 
osteoclastogenesis. To better understand how PLC2 controls Tmem178 expression, we utilized 
NFATc1-deficient (NFATc1Δ/Δ) precursors in which conditional deletion of NFATc1 is mediated 
by inducible Mx1-cre [36]. NFATc1fl/fl without Mx1-Cre served as control. Interestingly, 
RANKL-induced Tmem178 upregulation is blunted in NFATc1Δ/Δ cells compared to controls 
(Figure 3.2 D). These data position Tmem178 directly downstream of the RANKL-PLC2-
NFATc1 axis in the OC.    
Tmem178 deletion enhances osteoclastogenesis 
To determine the role of Tmem178 in the OC, we cultured bone marrow macrophages 
(BMMs) with M-CSF and RANKL for 3-5 days. Tmem178-/- BMMs display accelerated 
differentiation and increased OC numbers compared to WT (Figure 3.2 E-F). This rapid 
formation of multi-nucleated polykaryons is paralleled by an earlier and greater magnitude of 
induction of the early OC marker TRAP (Acp5), the functional protease Cathepsin K (CtsK), and 
calcitonin receptor (Calcr), a marker of committed OCs (Figure 3.2 G). To determine if 
Tmem178 affects OC resorptive activity, we cultured BMMs on bovine bone slices in the 
presence of M-CSF and RANKL for 10 days. Resorptive pit area was significantly increased in 
Tmem178-/- cultures compared to WT (Figure 3.2 H-I). Because enhanced resorption could be a 
consequence of increased OC numbers, we analyzed the resorptive capacity of individual OCs by 
plating committed OCs (differentiated on plastic with M-CSF and RANKL for 3 days) on bone 
slices for 48 hours. Results show equivalent bone resorption by Tmem178-/- and WT OCs 
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(Figure 3.2 J-K). Altogether these finding demonstrate that Tmem178 is a negative regulator of 
OC differentiation, but does not exert a direct effect on the cell’s resorptive capacity.  
Tmem178 negatively regulates OC formation by suppressing NFATc1 activation 
To understand how Tmem178 modulates OC differentiation, we assessed activation of 
RANKL signaling cascades including NF-B and MAPKs, JNK, ERK and p38. We find no 
perceptible differences in NF-B and MAPK activation between WT and Tmem178-/- BMMs 
(top) or preOCs (bottom) stimulated with RANKL (Figure 3.3 A). Similarly, M-CSF induction 
of p-AKT and p-ERK is equivalent in both genotypes (Figure 3.3 B). 
 NFATc1 is another important pathway activated during osteoclastogenesis in response to 
RANKL. Despite similar changes in NF-kB or MAPK activation, Tmem178-/- cells show 
heightened NFATc1 total protein and transcript levels throughout osteoclastogenesis (Figure 3.3 
C-D). Immunofluorescence staining of NFATc1 in BMMs shows only 1% of cells positive for 
nuclear NFATc1 in both genotypes (Figure 3.3 E). However, after 24 and 48 hours of RANKL 
stimulation, we observed a higher percentage of Tmem178-/- cells with NFATc1 nuclear 
staining compared to WT (Figure 3.3 E). Consistent with this finding, we also found a striking 
increase in NFATc1 nuclear translocation in Tmem178-/- preOCs compared to WT cells in 
response to a RANKL time course (Figure 3.3 F). Notably, no differences in NFATc1 protein or 
transcript levels are observed prior to RANKL exposure, indicating that Tmem178 acts 
downstream of RANKL to regulate NFATc1 induction. 
To confirm the proposed mechanism that Tmem178 suppresses osteoclastogenesis by 
limiting NFATc1 levels, we ectopically expressed Tmem178 in WT BMMs and analyzed their 
ability to induce NFATc1 and undergo OC differentiation. Tmem178-expressing cells show 
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attenuated NFATc1 levels compared to empty vector controls (Figure 3.3 G), with a resulting 
reduction in osteoclastogenesis (Figure 3.3 H, I). Altogether, these data indicate that Tmem178 
modulates osteoclast differentiation by suppressing RANKL-induced NFATc1 activation. 
Tmem178 modulates RANKL-induced Ca2+ fluxes 
High NFATc1 levels in Tmem178-/- cells could result from increased transcriptional 
activity of known NFATc1 regulators. IRF8 and Bcl6 are transcriptional repressors constitutively 
bound to the NFATc1 promoter and down-regulated within 24 hours of RANKL-RANK 
engagement [37]. qRT-PCR analysis revealed that mRNA levels of Bcl6 and IRF8 are reduced to 
a similar extent and with equivalent kinetics in WT and Tmem178-/- cells during 
osteoclastogenesis (Figure 3.4 A, B). Thus, Tmem178 does not seem to modify NFATc1 levels 
by targeting its transcriptional regulators.  
Alternatively, cytosolic Ca2+ fluxes stimulate the calmodulin/calcineurin pathway 
activating NFATc1 nuclear translocation. To test whether Tmem178 may restrain NFATc1 by 
affecting Ca2+ mobilization, we utilized ratiometric confocal imaging to measure Ca2+ in preOCs. 
Cells were loaded with Fura-2, a fluorescent Ca2+-binding dye; the ratio of Fura-2 fluorescence 
intensity following excitation at 340 and 380nm reflects intracellular Ca2+ concentration 
([Ca2+]i). The addition of exogenous RANKL induces the expected cytosolic Ca2+ oscillations in 
WT cells (Figure 3.4 C, average of 40-50 fluxing cells per genotype) while an immediate spike 
followed by sustained [Ca2+]i occurs in Tmem178-/- preOCs. Higher basal [Ca2+] i are already 
noted in Tmem178-/- preOC prior to the acute addition of RANKL. Quantification of the 
average Ca2+ measurements prior to any stimulation demonstrates that the majority of WT 
preOCs have a 340/380 ratio less than 1.0, while more than 60% of Tmem178-/- cells show a 
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340/380 ratio between 1.0-2.0 (Figure 3.4 D, more than 120 cells/genotype, data pooled from 3 
independent experiments). These data suggest that Tmem178 is a novel negative regulator of 
[Ca2+]i in the OC. 
To understand whether Tmem178 regulates cytosolic Ca2+ levels by affecting the ER 
pool or the extracellular exchange, we sought to first define Tmem178’s cellular localization. We 
expressed HA-tagged Tmem178 fusion protein (Tmem178-HA) in a puromycin-resistant 
retroviral vector in primary BMMs. Empty vector-expressing cells were used as a negative 
control. Cells surviving antibiotic selection were differentiated into OCs. Using phalloidin to 
stain polymerized actin at the cell membrane and calnexin as an ER marker, we found that 
Tmem178-HA localizes to the ER in mature OCs (Figure 3.4 E-F).  
We next wanted to examine how Tmem178 functions in the ER to modulate Ca2+ 
mobilization. WT and Tmem178-/- preOCs were treated with thapsigargin (Tg) in Ca2+-free 
buffer to measure ER Ca2+ release. Tmem178-/- preOCs show a greater increase in cytoplasmic 
[Ca2+] compared to WT cells (Figure 3.4 G). Importantly, this is not due to an increase in ER 
Ca2+ content, as ionomycin-triggered ER Ca2+ depletion in the presence of the Ca2+ chelator 
EGTA is equivalent in WT and Tmem178-/- preOCs (Figure 3.4 H, average of at least 70 
cells/condition and representative of 3 independent experiments).  
To confirm the role of Tmem178 as a negative regulator of ER Ca2+ mobilization, we 
expressed ectopic Tmem178 or pMX empty vector control in HEK293T cells. Upregulation of 
Tmem178 causes a slower and reduced increase in cytosolic [Ca2+] in response to Tg compared 
to cells transfected with pMX alone (Figure 3.4 I). Again, this effect is not due to a change in 
total ER Ca2+ concentration, as ionomycin-induced ER Ca2+ emptying is unchanged in 
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Tmem178-expressing cells versus controls (Figure 3.4 J). Suppression of ER Ca2+ release is in 
line with reduced NFATc1 expression and decreased osteoclastogenesis in primary OCs 
expressing exogenous Tmem178 (Figure 3.3 G- I). Taken together, these data establish the 
importance of Tmem178 as a negative regulator of ER Ca2+ mobilization.  
Tmem178 associates with Stim1  
 Next, we wanted to know if Tmem178 interacts with known ER-resident proteins 
involved in Ca2+ mobilization. Inositol triphosphate receptors (IP3Rs) are ER-resident Ca2+ 
channels, which facilitate ER Ca2+ release and consequent intracellular Ca2+ fluxes in response to 
IP3 generated by PLC signaling. All IP3Rs have been shown to be expressed in the OC, and 
IP3R2 and IP3R3 are compulsory for the generation of RANKL-stimulated Ca2+ fluxes [24]. 
Thus, we hypothesized that Tmem178 may be modulating ER Ca2+ mobilization by interacting 
with IP3Rs. However, using co-immunoprecipitation and immunofluorescence approaches, we 
were unable to detect the interaction between Tmem178 and any IP3Rs in primary OCs (data not 
shown).  
 Stim1 is a transmembrane ER Ca2+ sensor which interacts with numerous Ca2+ channels 
and adaptor proteins to regulate Ca2+ fluxes. Stim1 is expressed by the OC and regulates store-
operated Ca2+ entry (SOCE) through the association with Orai1. Targeting Stim1-mediated 
calcium entry suppresses osteoclastogenesis [25-27]. While Stim1 deletion abolishes SOCE, a 
modest defect in ER Ca2+ release was also previously noted in Stim1-deficient mast cells (Baba 
et al, 2008). Interestingly, new evidence suggests that Stim1 can potentiate IP3R-mediated ER 
Ca2+ release [38]. To determine if Tmem178 can bind Stim1, we expressed Tmem178-HA alone 
and in combination with Stim1-Myc in HEK293T cells. By immunoprecipitation of Tmem178-
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HA followed by Western blot for Stim1-Myc, we detected the association between Tmem178 
and Stim1 (Figure 3.5 A, first lane).  No bands were observed in cell lysates that did not express 
Stim1-Myc or in the IgG control (Figure 3.5 A second and third lane). Because Stim1 is best 
described for its coupling with Orai1, we also expressed Orai1-FLAG (Figure 3.5 B, C). We 
again found that Tmem178 and Stim1 interact, regardless of Orai1 expression (Figure 3.5 B, 
middle lane and Figure 3.5 C, third lane). In reciprocal co-IPs, we did not detect any interaction 
between Orai1 and Tmem178 (Figure 3.5 B, lane 1, Figure 3.5 C, bottom panel, lane 3), 
indicating that Tmem178 specifically interacts with Stim1. Additionally, the Stim1-Orai1 
interaction is intact in the presence of Tmem178 (Figure 3.5 C, first and second lanes). These 
data indicate that Tmem178 binds to Stim1, but not Orai1. 
 To determine whether Tmem178 and Stim1 interact in primary cells, we transduced WT 
BMMs with Tmem178-HA and Stim1-Myc retroviral vectors and cultured the expressing cells 
with RANKL for 24 hours. By confocal microscopy, we found that Tmem178 and Stim1 co-
localize in areas adjacent to the nuclei, presumably the ER (Figure 3.5 D, 4 representative fields). 
 Stim1 is most well-described in its role to activate store-operated Ca2+ entry (SOCE). To 
assess whether Tmem178 alters SOCE, we incubated Tmem178-/- preOCs and their WT 
counterpart with Tg in Ca2+-free buffer to deplete ER Ca2+ stores, followed by addition of 1.8 
mM Ca2+ to the medium. As shown in Figure 3.5 E, both genotypes achieve similar cytoplasmic 
Ca2+ concentrations in response to exogenous Ca2+ stimulation. A similar result was obtained in 
HEK293T cells expressing ectopic Tmem178 versus pMX vector control (Figure 3.5 F). 
Altogether, these findings indicate that Tmem178 is an ER protein that associates with Stim1. 
Tmem178 does not appear to participate directly in SOCE, however, but rather regulates Ca2+ 
mobilization out of the ER. 
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Tmem178-/- mice suffer profound inflammatory osteolysis 
Having shown that Tmem178 restrains ER Ca2+ mobilization to affect NFATc1 
upregulation and RANKL-induced OC differentiation, we wondered if Tmem178 similarly 
regulates OC formation driven by inflammatory cytokines. First, we observed that Tmem178 
mRNA expression is significantly increased in BMMs following exposure to inflammatory 
stimuli, including LPS (not shown). Second, we observed that the addition of TNF- or LPS, 
potent activators of pathological osteolysis, further exacerbates Tmem178-/- OC differentiation 
in vitro (Figure 3.6 A). Moreover, Tmem178-/- mice injected with LPS over the calvaria develop 
twice the eroded area compared to WT controls (Figure 3.6 B-C). This striking increase in 
resorption corresponds to a significant increase in OC surface in Tmem178-/- mice as shown in 
TRAP-stained histological sections (Figure 3.6 D-E).  
Next, we wanted to determine whether Tmem178 could modulate focal osteolysis in a 
model of inflammatory arthritis. Animals were injected with arthritogenic serum from K/BxN 
mice on days 0, 2, and 6 and sacrificed on day 14. Despite developing an equivalent 
inflammatory response to WT, measured by paw thickness and local production of inflammatory 
cytokines (data not shown), Tmem178-/- mice suffer significantly more bone loss, measured by 
remaining bone volume at the knee by CT (Figure 3.6 F-G), Analysis of the TRAP-stained 
histological sections of arthritic bones revealed that the excessive erosion in Tmem178-/- mice is 
driven by a significant increase in OC differentiation (Figure 3.6 H). All together these data 
indicate that loss of Tmem178 drives robust OC formation and excessive bone loss in 
inflammatory conditions.  
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Based on the above observations, we wondered whether changes in Tmem178 levels 
would be detected in patients affected by inflammatory conditions accompanied by bone erosion 
and increased osteoclastogenesis. Systemic juvenile idiopathic arthritis (sJIA) is a chronic 
disease characterized by systemic inflammation and arthritis [39]. Importantly, sJIA patients 
present with joint inflammation and erosive disease despite blockade of inflammatory cytokines 
[40, 41]. Low bone mass and increased risk of fragility fractures often persist in adulthood [5]. 
Thus, we hypothesized that sJIA pathogenesis may be related to Tmem178 dysregulation. Due to 
the difficulty of obtaining sufficient cellular samples from pediatric patients, we utilized the 
plasma of sJIA patients, which contains circulating factors capable of activating healthy human 
CD14+ PBMCs [42, 43]. We cultured CD14+ PBMCs from healthy donors with M-CSF and 
RANKL for 2 days to generate preOCs, and then added the plasma collected from healthy 
controls (n = 10) or sJIA patients (n = 20). Interestingly, we observed a significant reduction in 
Tmem178 transcript in CD14+ PBMCs treated with sJIA plasma compared to healthy control 
plasma (Figure 3.6 I). Confirming the Tmem178-/- OC phenotype, the addition of sJIA plasma 
potently augments OC differentiation compared to healthy plasma (Figure 3.6 J-K). Tmem178 
expression is further reduced, while OC numbers are significantly increased, following exposure 
to plasma from 5 patients with erosive disease compared to controls (Figure 3.6 I-K). Taken 
together, these data indicate that downregulation of Tmem178 levels may drive excessive 
osteoclastogenesis and contributes to erosive disease in sJIA.  
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3.6 Discussion 
Basal and pathological OC differentiation is dependent on Ca2+ fluxes initiated by the 
cytokine RANKL to activate the transcription factor NFATc1 [6, 8, 44]. Here we identify for the 
first time a role for Tmem178 as a negative regulator of NFATc1 by specifically limiting Ca2+ 
release from the ER (Figure 3.7). Tmem178 is upregulated by RANKL to restrain excessive OC 
differentiation in mice and humans. Tmem178 deficiency induces osteopenia, owing to a 
significant increase in OC numbers, and this phenotype becomes even more pronounced during 
inflammatory conditions in both mice and sJIA patients. This work provides new evidence for 
the importance of stringent control of Ca2+ mobilization to maintain bone mass and protect from 
pathological osteolysis.  
Amplitude and duration of dynamic Ca2+ signals have been shown to differentially 
modulate activation of various transcription factors. NFAT proteins have enhanced Ca2+ 
sensitivity compared to other transcription factors such as NF-kB or JNK, which enables NFAT 
transcriptional activation by low Ca2+ levels [45]. In the OC, a low but prolonged Ca2+ signal 
induces NFATc1 nuclear translocation and long-lasting nuclear localization throughout the 
osteoclastogenic process. We find that Tmem178-/- OC have higher basal intracellular Ca2+ 
levels than WT. Furthermore, in the OC, not only the amplitude of Ca2+ signaling but also the 
generation of continuous Ca2+ oscillations through the reduction and refilling of ER Ca2+  in 
response to RANKL is required for efficient NFATc1 transcriptional activation. Following 
RANKL exposure, Tmem178-/- cells reach higher intracellular Ca2+ levels compared to WT 
which correlate with greater NFATc1 induction and increased NFATc1 nuclear translocation. 
Consequently, Tmem178-/- cells undergo more rapid and robust osteoclastogenesis. We show 
that Tmem178 selectively modulates ER Ca2+ release, while not interfering with total ER Ca2+ 
95 
 
content or Ca2+ entry from the extracellular milieu. This result would suggest that Tmem178 
prevents Ca2+ leakage from the ER. In support of this assumption, ectopic expression of 
Tmem178 reduces thapsigargin-induced ER Ca2+ release and consequently suppresses NFATc1 
induction and osteoclastogenesis. It is important to note that ER Ca2+ leakage is only a fraction 
of the intracellular Ca2+ that can enter from the extracellular milieu. However, consistent with the 
differential functional consequences of Ca2+ signaling patterns, such as oscillations and spikes, 
this small but incremental difference in intracellular Ca2+ concentrations in KO cells exposed to 
RANKL can account for the heightened osteoclastogenic response that we observe in vitro and 
that persists in vivo.  
Due to the importance of Ca2+ amplitude and duration in discriminating between different 
response pathways, Ca2+ levels in the cells are tightly regulated. Regulators of Ca2+ channel 
activity in the OC have only recently come under investigation. Ong et al described the 
importance of transient receptor potential cation channel 1 to enhance store-operated calcium 
entry (SOCE) from the extracellular milieu during OC formation [46]. Similarly, Tmem64 
promotes RANKL-induced Ca2+ oscillations by bolstering the activity of Sarco-Endoplasmic 
Reticulum ATPase isoform 2, which actively re-fills ER Ca2+ stores, and is required for 
NFATC1 induction and osteoclastogenesis [28, 29, 47]. While these studies demonstrate that the 
loss of positive regulators of Ca2+ fluxes perturbs osteoclastogenesis and leads to increased bone 
mass, our work on Tmem178 is the first to identify a negative regulator of Ca2+ mobilization, 
whose ablation leads to an osteopenic phenotype. The relevance of our findings is bolstered by 
the significant reduction of Tmem178 expression levels in monocytes treated with plasma from 
sJIA patients with erosive disease. 
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 In pursuing the mechanism by which Tmem178 modulates Ca2+ oscillations, we found 
that Tmem178 and Stim1 co-immunoprecipitate. Stim1 is an ER Ca2+ sensor expressed in 
numerous cell types, including OCs, lymphocytes, mast cells, B cells, and T cells. 
Pharmacological inhibition of Stim1 impairs SOCE, thereby blocking osteoclastogenesis [27]. In 
addition to associating with Orai1 to control SOCE, Stim1 also couples to numerous other Ca2+ 
channels, Ca2+ pumps, ER chaperone proteins, and regulatory adaptor proteins, thereby 
influencing multiple pathways of Ca2+ transport [48]. In kidney epithelial cells, Stim1 interacts 
with polycystin-1, diminishing IP3R-mediated ER Ca2+ release [49]. Most recently, Stim1 has 
been shown to potentiate IP3R-mediated ER Ca2+ release in aortic endothelial cells [38]. In 
muscle cells Stim1 inhibits Ca2+ discharge from the sarcoplasmic reticulum [50]. Differences in 
ER Ca2+ release were also noted in Stim1-/- mast cells in response to antigen or thapsigargin 
[51]. Thus, Stim1 has a critical role not only in sensing ER Ca2+ levels and activating SOCE, but 
also appears to regulate, at least in part, ER Ca2+ release in multiple cell types. In the OC, we 
find that Tmem178 localizes to the ER where it associates with Stim1. Interestingly, Tmem178 
does not bind to Orai1 or inhibit Orai1-Stim1 coupling, and Orai1/Stim1-mediated Ca2+ entry is 
similar in both genotypes. Tmem178 also does not appear to associate with IP3Rs. While further 
studies are necessary to wholly understand the mechanism of Tmem178-mediated ER Ca2+ 
regulation and the significance of the Tmem178-Stim1 complex, we believe the Tmem178-Stim1 
interaction is an important observation which expands the understanding of Ca2+ regulation in 
the OC. 
Tmem178 interaction with Stim1 is particularly interesting in the context of arthritis. 
Stim1 single nucleotide polymorphisms (SNPs) were recently identified in patients with 
ankylosing spondylitis (AS), a chronic inflammatory disease of the spine and joints [52]. These 
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SNPs correlated with significantly higher inflammatory markers including C-reactive protein and 
in some cases higher circulating levels of TNF- and IL-6. In unpublished data, we found that 
Tmem178 negatively regulates TNF-, IL-1, and IL-6 production by macrophages. Although we 
did not have access to patient samples to measure Tmem178 levels or Tmem178/Stim1 binding 
in AS, we found that reduced Tmem178 expression is associated with augmented 
osteoclastogenesis in the context of sJIA. Further supporting a role for Tmem178 in 
inflammatory arthritis, Tmem178-/- mice suffer profound osteolysis following LPS and in 
K/BxN arthritis and in vitro studies show increased responsiveness to TNF-induced 
osteoclastogenesis.  
sJIA is characterized by arthritis and systemic inflammation. Bone erosion and systemic 
bone loss were observed in up to 50% of children with sJIA in the pre-biologic era. Even more 
recently, CARRAnet registry data (collected since 2010) on 435 children with sJIA show that 
joint damage remains a significant problem for at least 20% of these patients despite remission of 
the systemic inflammation (Janow et al., manuscript submitted).  Low bone mass and high risks 
of fragility fractures are also seen in adult patients who suffered from sJIA during childhood and 
adolescence [5]. Unfortunately, there are no markers that identify the subset of sJIA patients who 
will develop erosive disease.  Further, the diagnosis of sJIA is a clinical diagnosis of exclusion, 
and unfortunately a delayed diagnosis contributes to the development of erosive changes. We 
now show that Tmem178 expression is significantly reduced in human CD14+ PBMCs exposed 
to sJIA plasma, while OC differentiation is increased. We also observe a significant reduction in 
Tmem178 levels in samples treated with plasma from sJIA patients with erosive disease, 
positioning Tmem178 as a potential biomarker for the subset of sJIA patients who will develop 
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erosive disease. These initial findings with a limited number of patient samples necessitate future 
investigations with larger cohorts of sJIA patients.  
 Mechanistically, we do not yet understand the complex upstream mechanism which 
regulates Tmem178 expression in response to sJIA plasma. Moreover, in unpublished studies we 
find that Tmem178 also participates in inflammatory cytokine production, raising the possibility 
that Tmem178 may be important not only to the erosive aspect of sJIA but could contribute to 
the autoinflammatory symptoms of disease. Further investigation into the role of Tmem178 in 
the pathogenesis of sJIA is warranted. 
In conclusion, we have identified Tmem178 as a new PLC2-dependent gene. Despite its 
dependence on the RANKL-PLC2 pathway, however, Tmem178 acts in a negative feed back 
loop to restrain osteoclast responses in basal and pathological conditions. Moreover, we 
characterized the mechanism of Tmem178 to specifically modulate ER Ca2+ mobilization to 
repress NFATc1 induction. 
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3.9 Figure Legends 
Figure 3.1. Deletion of Tmem178 decreases bone mass in basal conditions 
A. Quantitative real-time PCR analysis of Tmem178 mRNA in whole tissues harvested from 
WT or PLC2-/- mice. Expression levels of Tmem178 were normalized to cyclophilin  
B.  Representative images of microcomputed tomography (CT) of the proximal femurs of 
16 week-old female WT and Tmem178-/- mice. WT n = 10, Tmem178-/- n = 11 
C. Trabecular bone volume per tissue volume (BV/TV) quantified from CT shown in (B). 
Data represent mean ± SD. Two-tailed student’s T-test was used to assess statistical 
significance, * p < 0.05 
D. Trabecular thickness (Tb.Th.) quantified from CT shown in (B). Data represent mean ± 
SD. Two-tailed student’s T-test was used to assess statistical significance, * p < 0.05 
E. Histological analysis of femurs analyzed in (B). Femurs were stained with TRAP to 
detect OCs and counterstained with hematoxylin. Arrows indicate OCs. 
F. Quantification of OC surface per bone surface (Oc.S/B.S.) in (E). n = 5/genotype. Data 
represent mean ± SD. Two-tailed student’s T-test was used to assess statistical 
significance, * p < 0.05 
G. Dynamic histomorphometry of calvaria from 4 week-old WT and Tmem178-/- mice 
labeled with calcein and alizarin red.  
H. Quantification of bone formation rate (BFR) of (G). n = 5/genotype. Data represent mean 
± SD. Two-tailed student’s T-test was used to assess statistical significance, * p < 0.05 
I. Quantification of mineral apposition rate (MAR) of (G). n = 5/genotype. Data represent 
mean ± SD. Two-tailed student’s T-test was used to assess statistical significance, * p < 
0.05 
 
Figure 3.2. Tmem178 deficiency enhances osteoclastogenesis  
A. Quantitative real-time PCR analysis of Tmem178 mRNA in WT BMMs, mature OCs, 
and mature OBs cultured in vitro. Expression levels of Tmem178 were normalized to 
cyclophilin levels. 
B. Quantitative real-time PCR analyses of Tmem178 mRNA during RANKL-induced 
osteoclastogenesis in vitro in WT and PLC2-/- cells. WT and PLC2-/- BMM were 
cultured with 10 ng/ml M-CSF and 50 ng/ml RANKL for the indicated days. Expression 
levels of Tmem178 were normalized to cyclophilin levels. Representative of 3 
experiments. 
C. Quantitative real-time PCR analysis of Tmem178 mRNA in human CD14+ PBMCs 
cultured in vitro with 50 ng/ml RANKL for indicated time points. Expression levels of 
Tmem178 were normalized to cyclophilin levels. Data represent mean ± SD. Two-tailed 
student’s T-tests was used to assess statistical significance, * p < 0.05 
D. Expression of Tmem178 mRNA during RANKL-induced osteoclastogenesis in vitro in 
control (NFATc1fl/fl) and NFATc1-deficient cells (NFATc1Δ/Δ). Controls and NFATc1Δ/Δ 
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BMMs were cultured with 10 ng/ml M-CSF and 50 ng/ml RANKL for the indicated 
days. Tmem178 expression levels were normalized to cyclophilin. Data represent mean ± 
SD. Two-tailed student’s T-test was used to assess statistical significance, * p < 0.05. 
E. TRAP staining of WT and Tmem178-/- OCs in vitro after 4 days of culture with 10 ng/ml 
M-CSF and 50 ng/ml RANKL. Images are representative of more than 5 experiments, 
each performed in triplicate. 
F. Quantification of TRAP+ OCs in WT and Tmem178-/- cultures after 3 and 4 days of 
culture with 10 ng/ml M-CSF and 50 ng/ml RANKL.  Triplicate wells were counted for 
each condition, and data are representative of more than 5 experiments. Data represent 
mean ± SD, * p < 0.05, *** p < 0.001 
G. Quantitative real-time PCR analysis of osteoclastogenic markers in WT and Tmem178-/- 
cells collected at the indicated days of culture with 10 ng/ml M-CSF and 50 ng/ml 
RANKL. Acp5, TRAP; Ctsk K, Cathepsin K. CalcR, calcitonin receptor. Expression 
levels of each marker were normalized to cyclophilin. Data represent the mean ± SD, ** 
p < 0.01, *** p < 0.0001, n = 3 independent experiments 
H. Representative bright field images of resorptive pits in WT and Tmem178-/- cultures. 
WT and Tmem178-/- BMMs were cultured on bovine bone slices in the presence of 10 
ng/ml M-CSF and 50 ng/ml RANKL for 10 days. Resorption pits were visualized by 
staining with peroxidase-conjugated wheat-germ agglutinin. Black lines delineate the 
resorbed areas. 
I. Quantification of resorbed area in images from (H). n = 8-9/ genotype. Data represent 
mean ± SD, * p < 0.05.  
J. Representative bright field images of resorptive pits in WT and Tmem178-/- cultures. 
WT and Tmem178 BMM were cultured on plastic dishes with 10 ng/ml M-CSF and 50 
ng/ml RANKL for 3 days. Cells were then lifted and re-plated on bovine bone slices in 
the presence of 10 ng/ml M-CSF and 50 ng/ml RANKL for 48 hours. Resorption pits 
visualized by staining with peroxidase-conjugated wheat-germ agglutinin. Black lines 
delineate the resorbed areas. 
K. Quantification of resorbed area in images from (J). n = 8-9/ genotype. Data represent 
mean ± SD, ns  
 
Figure 3.3. Tmem178 negatively regulates the Ca2+-NFATc1 signaling pathway 
A. Western blot analysis of RANKL-induced MAPK and NF- - 
WT and Tmem178-/- BMMs were serum- and cytokine- starved overnight, and 
stimulated with 50 ng/ml RANKL for the indicated time points. Total Pyk2 is shown as 
loading control. Bottom panels- WT and Tmem178-/- preOCs were cultured with 10 
ng/ml M-CSF and 50 ng/ml RANKL for 2 days, serum- and cytokine-starved for 6 hours, 
and stimulated with 50 ng/ml RANKL for the indicated time points. Actin is shown as 
loading control. Representative of 3 experiments. 
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B. Western blot analysis of M-CSF-induced AKT and ERK phosphorylation. Top panels- 
WT and Tmem178-/- BMMs were serum- and cytokine- starved overnight, and 
stimulated with 100 ng/ml recombinant M-CSF for the indicated time points. Total Pyk2 
is shown as loading control. Bottom panels- WT and Tmem178-/- preOCs were cultured 
with 10 ng/ml M-CSF and 50 ng/ml RANKL for 2 days, serum- and cytokine-starved for 
6 hours, and stimulated with 100 ng/ml M-CSF for the indicated time points. Actin is 
shown as loading control. Representative of 3 experiments. 
C. Western blot analysis of NFATc1 total protein levels at the indicated time points of 
osteoclastogenesis. WT and Tmem178-/- BMMs were cultured with 10 ng/ml M-CSF 
and 50 ng/ml RANKL for the indicated number of days. Total ERK levels are shown as 
loading control. Representative of 3 experiments. 
D. Quantitative real-time PCR analysis of NFATc1 mRNA at the indicated days of 
osteoclastogenesis. WT and Tmem178-/- BMM were cultured with 10 ng/ml M-CSF and 
50 ng/ml RANKL for the indicated number of days. NFATc1 expression levels were 
normalized to cyclophilin. Data represent the mean ± SD, ** p < 0.01, n = 3 independent 
experiments 
E. Quantification of NFATc1 nuclear localization by immunofluorescence. WT and 
Tmem178-/- BMMs were plated on glass coverslips and cultured with 10 ng/ml M-CSF 
and 50 ng/ml RANKL for the indicated number of days. Data are pooled from 2 
independent experiments, 3-9 coverslips/condition/experiment. Cells were stained for 
NFATc1 and DAPI to detect nuclei. Data represent the mean ± SD, * p < 0.05 
F. Western blot analysis of NFATc1 nuclear translocation in response to RANKL. WT and 
Tmem178-/- BMMs were cultured with 10 ng/ml M-CSF and 50 ng/ml RANK for 2 
days, serum- and cytokine- starved for 6 hours, and stimulated with 50 ng/ml RANKL for 
the indicated time points. Lamin B is shown as loading control. Representative of 3 
experiments. 
G. Quantitative real-time PCR analysis of NFATc1 transcript levels during 
osteoclastogenesis in WT cells expressing empty vector pMX or Tmem178-HA. BMMs 
expressing pMX or Tmem178-HA were cultured with 10 ng/ml M-CSF and 50 ng/ml 
RANKL for the indicated number of days. NFATc1 expression levels were normalized to 
cyclophilin. Data represent the mean ± SD, ** p < 0.01, *** p < 0.0001, n = 3 
independent experiments 
H. Representative images of TRAP staining of OCs expressing pMX empty vector or 
Tmem178-HA  in vitro after 4 days of culture with 10ng/ml M-CSF and 50ng/ml 
RANKL.  
I. Quantification of OC area in (h). Data represent the mean ± SD, ** p < 0.01, n = 
3/condition, representative of more than 3 experiments.  
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Figure 3.4. Tmem178 modulates ER Ca2+ mobilization   
A. Quantitative real-time PCR analysis of Bcl6 transcript levels during osteoclastogenesis in 
WT and Tmem178-/- cells cultured with 10ng/ml M-CSF and 50ng/ml RANKL for the 
indicated days. Bcl6 expression levels were normalized to cyclophilin. Data represent the 
mean ± SD. n = 3 independent experiments.  
B. Quantitative real-time PCR analysis of IRF8 transcript levels during osteoclastogenesis in 
WT and Tmem178-/- cells cultured with 10 ng/ml M-CSF and 50 ng/ml RANKL for the 
indicated days. IRF8 expression levels were normalized to cyclophilin. Data represent 
then mean ± SD. n = 3 independent experiments. 
C. Cytosolic Ca2+ measurements in primary preOC by ratiometric confocal imaging. WT 
and Tmem178-/- BMMs were cultured with 10 ng/ml M-CSF and 50 ng/ml RANKL for 
1-2 days to generate preOCs. Cells were loaded with 3M Fura-2 in phenol red-free 
DMEM and stimulated with 100ng/ml RANKL in the presence of extracellular Ca2+. 5 
representative tracings of single cells are shown for WT and Tmem178-/- preOC. 
D. Percent of WT and Tmem178-/- preOCs with low Ca2+ (Fura-2 ratio < 1) or high Ca2+ 
(Fura-2 ratio >1). The Fura-2 ratio of each cell was averaged over the first 60 seconds of 
imaging. Data was pooled from 3 experiments, combining more than 120 cells/genotype. 
E-F. Localization of Tmem178 in mature OCs by immunofluorescence. BMMs expressing 
 pMX or Tmem178-HA were cultured on coverslips with 10ng/ml M-CSF and 
 100ng/ml RANKL for 5 days. Phalloidin was used as a plasma membrane marker, 
 calnexin was used as an ER marker and DAPI was used as a nuclear stain. Scale  bar 
 indicates 100 m. Manually contoured white line denotes cell edge.  
G. ER Ca2+ release measured by ratiometric confocal imaging of primary WT and 
 Tmem178-/- preOCs, imaged in the presence of Ca2+-free HBSS and treated with 1 M 
 Tg to measure ER Ca2+ release. Fura-2 340/380 ratios are the mean of at least 70 
 cells/condition, representative of 3 independent experiments. 
H. Total ER Ca2+ content measured by ratiometric confocal imaging of primary WT and 
Tmem178-/- preOCs, imaged in the presence of Ca2+-free HBSS containing 2mM EGTA. 
Cells were stimulated with 10M ionomycin to trigger ER Ca2+ depletion. Fura-2 
340/380 ratios are the mean of at least 70 cells/condition, representative of 3 independent 
experiments. 
I. ER Ca2+ release detected by ratiometric imaging of cytosolic Ca2+ of HEK293T cells 
expressing empty vector or Tmem178-HA. C 2+-free 
HBSS to measure ER Ca2+ release. Fura-2 340/380 ratios represent the mean of at least 
100 cells/condition, representative of 2 independent experiments. 
J. Total ER Ca2+ content detected by ratiometric confocal imaging of HEK293T cells 
expressing empty vector or Tmem178- 2+-
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free HBSS containing 2mM EGTA. Fura-2 340/380 ratios represent the mean of at least 
100 cells/condition. representative of 2 independent experiments. 
 
Figure 3.5. Tmem178 associates with Stim1 in the ER   
A. Co-immunoprecipitation of Tmem178 and Stim1. Top panel- HEK293T cells expressing 
Tmem178-HA alone or with Stim1-Myc were lysed, and subjected to 
immunoprecipitation with anti-HA antibody or control IgG. IP WB was probed with Myc 
tag antibody. Total cell lysates were blotted for Myc and HA.  
B. Co-immunoprecipitation of Tmem178 and Stim1 in HEK293T cells expressing 
Tmem178-HA, Stim1-Myc, and Orai1-FLAG. Top panel-lysates were subjected to 
immunoprecipitation with anti-FLAG, anti-Myc, or IgG control antibodies, and Western 
blotted for HA to detect an association with Tmem178. Total cell lysates (bottom panel) 
were probed for FLAG, Myc, and HA to show co-expression of all proteins.  
C. Co-immunoprecipitation of Stim1 with Tmem178 and Orai1. HEK293T cells expressing 
Tmem178-HA, Stim1-Myc, and Orai1-FLAG were immunoprecipitated with the 
indicated antibodies and Western blotted for Myc and FLAG (Top panel). Total cell 
lysates (bottom panel) were probed for FLAG, Myc, and HA to show co-expression of all 
proteins. 
D. Representative confocal images of Tmem178 and Stim1 co-localization in primary cells. 
BMMs co-expressing Tmem178-HA and Stim1-Myc were plated on glass coverslips in 
the presence of 10 ng/ml M-CSF and 50 ng/ml RANKL for 24 hours. Cells were stained 
with a FITC-conjugated anti-HA antibody and anti-Myc tag antibody. Myc was detected 
using an Alexa Fluor 543 secondary antibody. Dapi was used for nuclear staining.  
E.-F. SOCE was measured in WT and Tmem178-/- cells cultured with 10 ng/ml M-CSF and 50 
 ng/ml RANKL for 24 hours (E) and HEK293T cells expressing empty vector or ectopic  
 Tmem178 (F). Cells were loaded with 3 M Fura-2 in Ca2+-free HBSS then treated 
 with Thapsigargin (Tg) to release ER Ca2+. 1.8 mM Ca2+ was then added back to the 
 buffer to measure SOCE.  
Figure 3.6. Tmem178 deletion worsens inflammatory bone loss 
A. Quantification of TRAP+ OCs in WT and Tmem178-/- cells cultured with 10 ng/ml M-
CSF and 100 ng/ml RANKL alone, or with the addition of 100 ng/ml LPS or 10 ng/ml 
TNF- on day 2 of OC culture. Data represent the mean ± SD, *** p < 0.0001 ** p < 
0.01, n = 3  
B. Representative CT 3D reconstructions of calvaria from WT and Tmem178-/- mice 
receiving 100 µg supracalvarial LPS on day 0. Calvaria were harvested on day 5 after 
LPS.  
C. Quantification of the percent area resorbed on the calvaria from images shown in (B). 
Data represent the mean ± SD, ** p < 0.01, n = 10/genotype 
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D. Representative images of histological sections from calvaria shown in (B) stained with 
TRAP to detect OCs and counterstained with hematoxylin. Arrows indicate OCs.  
E. Quantification of TRAP+ OC in (D).  Data are expressed as OC surface per bone surface 
(Oc.S./B.S.). Data represent the mean ± SD, ** p < 0.01, n = 10/genotype 
F. -/- mice 
harvested on day 14 after 3 injections of K/BxN serum on days 0, 2 and 6 to induce 
inflammatory arthritis. n = 9/genotype. 
G. Quantification of bone volume remaining at the knee in mice in (F). Data represent the 
mean ± SD, ** p < 0.01, n = 10/genotype 
H. Quantification of TRAP+ OCs on TRAP-stained histological sections from knees of WT 
and Tmem178-/- mice in (F) . Data are expressed as OC surface per bone surface 
(Oc.S/B.S.) Data represent the mean ± SD, ** p < 0.01, n = 10/genotype 
I. Quantitative real-time PCR analysis of Tmem178 mRNA expression in human CD14+ 
PBMCs from healthy donor were cultured with 30 ng/ml hM-CSF and 100 ng/ml 
RANKL for 2 days. Plasma from healthy controls or sJIA patients was added to the 
cultures for 8 hours. Tmem178 expression is normalized to cyclophilin expression. Data 
represent the mean ± SD, ** p < 0.01, * p < 0.05.  
J. Quantification of area covered by TRAP+ OCs cultured with healthy control plasma or 
sJIA patient plasma. Human CD14+ PBMCs from healthy donor were cultured with 30 
ng/ml hM-CSF and 100 ng/ml RANKL for 5 days. Plasma from healthy controls or sJIA 
patients was added on day 2 of osteoclastogenesis and replenished at media change every 
other day. Data represent the mean ± SD, * p < 0.05. Triplicate wells were counted for 
each plasma sample, and data are representative of 3 independent experiments. 
K. Representative images of TRAP staining of OCs treated with healthy control plasma or 
sJIA patient plasma quantified in (j) 
Figure 3.7. Model of Tmem178 function.  
In the WT OC, Tmem178 represses ER Ca2+ release, thereby limiting cytosolic Ca2+, 
NFATc1 activation, and osteoclastogenesis. In Tmem178-/- OCs, augmented ER Ca2+ 
release increases cytosolic Ca2+ levels, thereby amplifying NFATc1 activation leading to 
excessive osteoclastogenesis.   
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Chapter 4. The Role of Tmem178 in the Regulation of the Macrophage Inflammatory 
Response 
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4.1 Up-regulation of Tmem178 in inflammatory macrophages is essential to the control of 
systemic inflammation 
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4.2 Abstract 
Pathological bone loss in human disease such as rheumatoid arthritis is largely due to 
excessive osteoclast recruitment and activation as a consequence of localized inflammation. 
PLC2-deficient mice are protected from inflammatory arthritis due to impaired neutrophil 
inflammatory responses.  We now report that PLCγ2-/- bone marrow macrophages (BMM) 
display impaired NF-kB activation leading to reduced IL-1, IL-6 and TNFα mRNA levels 
following adhesion, suggesting that PLCγ2 controls the development of inflammation in innate 
immune cells. By a gene array approach, we identified Tmem178 as a novel PLC2 effector 
whose expression is highly induced by integrin-mediated adhesion and TLR activation in WT 
but not PLC2-/-macrophages. In contrast to PLC2-/- macrophages, we find that Tmem178-/- 
BMMs have a striking increase in inflammatory cytokine expression in response to adhesion and 
TLR stimulation. Mechanistically, Tmem178 targets Ca2+ fluxes downstream of TLR and 
integrin signaling to affect NFAT activation, thus dampening inflammatory cytokine 
transcription. Most importantly, Tmem178-null mice succumb faster to endotoxin-induced 
sepsis, indicating that Tmem178 functions in a novel negative feedback loop downstream of 
PLCγ2 to repress inflammation. These results are consistent with our previous observation 
reporting a reduction Tmem178 levels in the context of sJIA. Our data demonstrate a role for 
Tmem178 in controlling inflammation as well, positioning Tmem178 as an essential regulatory 
component in both the inflammatory and erosive arms of inflammatory arthritis.   
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4.3 Introduction 
In arthritic conditions, chronic inflammation drives activation of the bone-resorbing 
osteoclast leading to bone resorption and progressive joint disease. An influx of leukocytes cells 
into the joint is a hallmark of inflammatory arthritis. Innate immune cells, namely neutrophils 
and macrophages, infiltrate the joint space and release pro-inflammatory cytokines including 
TNF-a, IL-1, and IL-6 as well as proteases to drive local tissue damage and inflammation. 
Importantly, IL-1 and TNF- in particular potently augment osteoclast differentiation and thus 
bone resorption (1-7). Thus, suppressing the inflammatory response is fundamental to the 
efficacy of arthritis treatments. Current therapeutics such as disease-modifying anti-rheumatic 
drugs (DMARDs) and cytokine inhibitors, however, are not successful at controlling 
inflammation in all patients (8).  
Patients suffering from systemic juvenile idiopathic arthritis (sJIA) exhibit dramatically 
elevated levels of inflammatory cytokines, specifically IL-1 and TNF-, within the synovial 
fluid and in circulation (9, 10).  sJIA is an episodic auto-inflammatory disease that, unlike other 
arthritic subtypes, is primarily driven by innate immune cells. Expanded monocyte numbers, 
particularly during episodes of disease flare, are observed in sJIA patients (9). Approximately 
10% of sJIA patients develop MAS, which is responsible for the majority of the morbidities 
associated with sJIA.  The onset of MAS is sudden, and patients present with high fever, 
hepatosplenomegaly, lymphadenopathy, cutaneous and mucosal bleeding, pancytopenia, as well 
as central nervous system, cardiac, and renal involvement. Importantly, MAS is so-named due to 
a massive influx of activated macrophages in the bone marrow, liver and spleen. (10, 11). It is 
actually unknown if this increase in macrophages is driving pathogenesis or is an attempt to 
control a dysregulated adaptive immune response (12). The sJIA/MAS field is currently lacking 
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a clear picture of how the activated monocyte/macrophage population functions at both a cellular 
and molecular level during the onset and course of disease.   
We have previously reported that PLC2-deficient mice are osteopetrotic due to defective 
OC formation and are protected from joint inflammation and destruction during serum-transfer 
arthritis, a model strictly dependent on neutrophil and macrophage activation (13, 14). The 
aberrant inflammatory response observed in PLCγ2-/- mice was dependent on reduced 
production of inflammatory cytokines IL-1, IL-6 and TNF-α by local innate immune cells. We 
also have previously shown that specifically targeting PLC2 scaffolding domains in vivo can 
block the osteoclast and ameliorate the erosive pathology of inflammatory osteolysis, but this 
approach is not sufficient to dampen inflammation (15). Thus, to better understand PLCg2-
dependent genes which could modulate a pro-inflammatory immune response we performed a 
gene array comparing WT and PLC2-/- BMMs plated on integrin substrate. Herein we identify 
Tmem178 as a novel molecule that represses the pro-inflammatory response of macrophages, in 
vitro and in vivo. This observation in concert with our previous finding that Tmem178 levels are 
reduced in CD14 monocytes exposed to plasma from sJIA patients, raise the possibility that 
Tmem178 is a new gene of interest in the pathogenesis of sJIA and the associated disorder MAS.  
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4.4 Materials and Methods 
Mice  
PLC2-/- mice were kindly provided by Dr. JN Ihle (St. Jude Children’s Research Hospital, 
Memphis, Tennessee, USA). Tmem178-/- mice (Strain B6;129S5-Tmem178tm1Lex/Mmucd) 
were generated by the trans-NIH Knock-Out Mouse Project (KOMP) and purchased from the 
KOMP Repository at UC Davis (www.komp.org) (stock number 032664-UCD). Tmem178-/- 
C57Bl/6-SvEv129 mice were transferred to the pure C57Bl/6 background by speed congenics, 
and maintained on the C57Bl/6 background by homozygous breeding. Perforin-/- (prf-/-) 
breeding pairs were purchased from Jackson Labs (Strain Name:C57BL/6-Prf1tm1Sdz/J Stock 
Number: 002407) and maintained by homozygous breeding. C57Bl/6 Tmem178-perforin double 
knock out mice were generated in-house. All experiments were approved by the Washington 
University School of Medicine animal care and use committee.  
Primary cell culture 
 Bone marrow was isolated from long bones of 6- to 8-week-old C57BL/6 mice and cultured in 
alpha-MEM containing 10% heat-inactivated fetal bovine serum, 100 IU/ml penicillin, and 100 
μg/ml streptomycin, and glutamine (α-10 medium), with 1/10 vol CMG14-12 cell-conditioned 
medium as a source of macrophage colony-stimulating factor (M-CSF) (16) to obtain bone 
marrow-derived macrophages (BMMs).  Resident peritoneal macrophages were harvested from 
6- to 8-week-old C56Bl/6 mice by lavage. Briefly, the peritoneum was washed with 4 ml of 
sterile PBS, exudate was collected, and recovered cells were washed in sterile PBS. Cells were 
cultured in vitro with DMEM containing 10% heat-inactivated fetal bovine serum, 100 IU/ml 
penicillin, and 100 μg/ml streptomycin, and glutamine.  
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Gene array 
Petri dishes were coated with Arg-Gly-Asp (pRGD) in PBS overnight at 4°C. WT and PLCg2-/- 
BMMs were serum- and cytokine- starved overnight, lifted with trypsin-EDTA, and 2 × 106 cells 
were plated on pRGD-coated dishes for 4 hours.  Non-adherent cells were in suspension for 4 
hours. Cells were lysed in TRIzol and RNA was extracted by RNeasy Mini kit (Qiagen). mRNA 
profiles were analyzed by Affymetrix Mouse Gene 430 2.0 array. 
Western blot and antibodies  
For signaling assays, BMMs were starved overnight in overnight in cytokine- and serum-free 
alpha medium. For adhesion assays, petri dishes were coated with Arg-Gly-Asp (pRGD) in PBS 
overnight at 4°C. Starved BMMs were lifted with trypsin-EDTA, and plated on pRGD-coated 
dishes for the indicated time points. For LPS stimulation, starved BMMs were treated with 1 
ug/ml LPS from Escherichia coli 0111:B4 (Sigma) in cytokine- and serum free alpha medium for 
the indicated time points. For total cell lysates, BMMs or preOCs were lysed in RIPA buffer 
supplemented with protease/phosphatase inhibitor cocktail (Pierce). Protein concentration was 
determined by bicinchoninic acid protein assay (Biorad), resolved by SDS-page and subjected to 
western blot analysis. For immunoblotting phospho-ERK (D13.14.4E), phospho-JNK (81E11), 
phospho-p38 (3D7), phospho-IκBα (14D4), Pyk2 (3292), and ERK (9102) monoclonal 
antibodies were obtained from Cell Signaling Technology. Actin was purchased from Sigma. 
NFATc1 (7A6) was purchased from Santa Cruz, as well as secondary anti-mouse and anti-rabbit 
HRP-conjugated antibodies. 
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 Ratiometric Ca2+ imaging 
For Ca2+ flux assays, 500 000 BMMs were seeded in 29mm glass bottom dishes (In Vitro 
Scientific). Cells were cultured with 1 ug/ml LPS in alpha-mem media for 16 hours. Cells were 
loaded with 3 M Fura-2-AM (Invitrogen) in phenol red-free DMEM (Invitrogen) .Cells were 
washed twice with HBSS and imaged immediately in phenol red-free DMEM containing 1ug/ml 
LPS. Fura-2 ratios were measured by alternate excitation at 340 nm and 380 nm. A Till 
Photonics digital microscopes equipped with Polychrome V monochromators, Fura-2 (340/380) 
filter set, a 20X 0.3NA objective lens, and high resolution (1344×1200) cooled CCD camera was 
used to capture images at a frequency of 1 image pair every 2 seconds. Data were acquired and 
analyzed using Live Acquisition software.  
Real-time PCR  
Adherent cells were lysed in Trizol. Total RNA was isolated using the RNeasy Mini Kit 
(Qiagen) and reverse transcribed to cDNAs using EcoDry Premix (Oligo dT) (Clontech).1 μg of 
total RNA was reverse transcribed to cDNA using SuperScript II according to the manufacturer’s 
instructions (Invitrogen).  For real-time PCR, SYBR Green PCR Master Mix (Applied 
Biosystems) and primers specific for murine Tmem178, IL-1, IL-6, TNF-a, NFATc1, NFATc3, 
and cyclophilin were used as follows for Tmem178, ATGACAGGGATATTTTGCACCAT 
(forward) and CCGGTTCAAGTCATAGGAGACACT (reverse);  IL-1, 
GCTTCCTTGTGCAAGTGTCTGA (forward) and TCAAAAGGTGGCATTTCACAGT 
(reverse); for IL-6, TTCTCTGGGAAATCGTGGAAA (forward) and 
TGCAAGTGCATCATCGTTGTT (reverse); for TNFα, CTGTAGCCCACGTCGTAGC 
(forward) and TTGAGATCCATGCCGTTG (reverse); for NFATc1,  
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CCCGTCACATTCTGGTCCAT (forward) and CAAGTAACCGTGTAGCTGCACAA 
(reverse); for NFATc3 GCTCGACTTCAAACTCGTCTT (forward) and 
GATGTGGTAAGCCAAGGGATG (reverse) for cyclophilin AGCATACAGGTCCTGGCATC 
(forward) and TTCACCTTCCCAAAGACCAC-3’ (reverse). SYBR green dye was used for 
detection of the product using the SYBR Green PCR Master Mix assay (Applied Biosystems). 
The standard curve used a series of duplicate dilutions of plasmid for each gene and cyclophilin 
cDNA. The amplification reaction was performed for 40 cycles with denaturation at 95°C for 10 
minutes, followed by annealing at 95°C for 15 seconds and extension and detection at 60°C for 1 
minute. The relative abundance of each target was calculated as 1000×2−(Ct target gene−Ct 
cyclophilin), where Ct represents the threshold cycle for each transcript, and cyclophilin is the 
reference. 
LPS-induced sepsis 
WT and Tmem178-/- C57Bl/6 mice were injected with 25 mg/kg Lipopolysaccharides (LPS) 
from Escherichia coli 0111:B4 (Sigma). Blood was collected by submandibular bleed 2 hours 
after LPS administration, and serum was harvested by centrifugation at 8000g for 5 minutes at 4 
degrees. Serum cytokines were measured using the mouse inflammatory cytometric bead array 
(BD Biosciences).  
LCMV-induced MAS 
LCMV-WE viral stocks were kindly provided by Dr. Maria Salvato (University of Maryland). 
For LCMV infections, mice were administered 104  PFU of LCMV-WE injected intravenously. 
PBS- and clodronate-loaded liposomes were purchased from www.clodronateliposomes.org.  For 
macrophage depletion, mice were administered 200 ul of clodronate-loaded liposomes 
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intravenously. Control mice received 200 ul of empty liposomes. Mice were monitored for 
survival, or sacrificed on the indicated days for macrophage population analysis. To measure 
serum cytokines, blood was collected via submandibular bleed and irradiated by exposure to UV 
for 30 minutes. Serum was isolated via centrifugation at 8000 g for 5 minutes at 4 degrees. 
Serum cytokines were measured using a mouse inflammatory Cytometric Bead Array (BD 
Biosciences).  
Flow cytometry  
Immediately upon sacrifice, single-cell suspensions were prepared from spleen and liver. Single 
cell suspensions were generated by physical disruption and passage through a .70 um cell filter 
followed by red blood cell lysis. Cell suspensions were then washed once and stained in PBS 
with 0.5% FBS with the following anti–mouse antibodies: FITC-conjugated anti-F4/80 
(eBioscience) or PerCP-Cy5.5-conjugated F4/80 (eBioscience); phycoerythrin (PE)-conjugated 
antibodies to CD11b (BD), Alex Fluor 647-conjugated CD206 (Serotec), PE-Cy5- conjugated 
CD80 (B7-1) (eBioscience), and eFluor 450-conjugated MHC Class II (eBioscience). The 
respective isotype-matched conjugated controls were purchased from eBioscience, BD, and 
Serotec. Acquisition was performed on a FACSCalibur or Fortessa and the dedicated software 
CellQuest (BD). Data were analyzed with FlowJo 7.5.5 software (Tree Star). 
Statistics  
All data represent mean ± SD. Data were analyzed using two-tailed Student’s t test, with a P 
value of <0.05 set as statistically significant. *p<0.05 **p<0.01, ***p<0.001 
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4.5 Results 
PLC2 regulates pro-inflammatory gene transcription in macrophages 
We previously found that PLC2-/- mice are protected from inflammation in the K/BXN model 
of serum-transfer arthritis which is strongly dependent on the neutrophil pro-inflammatory 
response. Mechanistically, PLC2 is required for neutrophil degranulation in response to 
integrin-mediated adhesion (14). We hypothesized that PLC2 modulates a similar pro-
inflammatory pathway downstream of integrin in macrophages. WT and PLC2-/- bone marrow 
macrophages (BMMs) were plated on the generic integrin ligand Arg-Gly-Asp (pRGD) for 2 and 
4 hours. WT BMMs significantly upregulate transcript levels of TNF-, IL-1, and IL-6 after 2 
and 4 hours of integrin adhesion, compared to WT cells in suspension (Figure 4.1 A ). This 
inflammatory response is abrogated in BMMs lacking PLC2-/-. NF-kB is a transcription factor 
critical for induction of inflammatory responses and cytokine production. We hypothesized that 
PLC2 modulates inflammatory cytokine transcription via NF-kB activation. In WT cells, 
integrin ligation induces rapid phosphorylation of IKB, an indicator of NF-kb pathway 
induction (Figure 4.1 B). IKB phosphorylation is significantly blunted in PLC2-/- BMMs, 
however. Thus, downstream of integrin ligation, PLC2 induces NF-kB activation to turn on 
inflammatory cytokine production.  
In the osteoclast, both PLC2’s catalytic and scaffolding motifs are necessary to generate 
downstream signal transduction (15, 17) To determine which domain(s) of PLC2 are mediating 
this NF-kB activation, we expressed full-length PLC2 or PLC2 constructs harboring mutations 
in the catalytic or SH2 scaffolding domain in PLC2-/- BMMs. Expression of full-length PLC2 
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rescued IKB phosphorylation in PLC2-/- cells stimulated on pRGD. Cells expressing 
catalytically inactive PLC2, however, were still unable to activate NF-kB, while the SH2 
domain appears to be dispensable in this pathway (Supplementary Figure 4.1). Collectively, 
these data suggest that PLC2 controls the induction of a pro-inflammatory pathway in activated 
macrophages.  
Tmem178 is a PLC2-dependent gene in inflammatory macrophages 
 To identify specific downstream modulators of this PLC2-dependent pro-inflammatory 
pathway, we performed a gene array experiment comparing WT and PLC2-/- BMMs plated on 
pRGD. Transmembrane protein 178 (Tmem178) was highly induced in WT BMMs after 4 hours 
of adhesion (Figure 4.1 C). PLC2-/- BMMs, however, failed to upregulate Tmem178 transcript. 
We next asked what other inflammatory stimuli can induce Tmem178 expression. Confirming 
the gene array, Tmem178 transcript levels are significantly upregulated in WT BMMs plated on 
pRGD. LPS treatment also strongly upregulates Tmem178 (Figure 4.1 D). On the other hand, 
Tmem178 expression is low in neutrophils, dendritic cells (DCs), and is not detected in T cells. 
These results position Tmem178 as a specific modulator of the pro-inflammatory macrophage, 
acting downstream of PLC2.  
Tmem178-/- mice are more susceptible to sepsis 
 We have previously described the impaired inflammatory response of PLC2-/- mice in 
the context of arthritis (14). PLC2 has previously been shown to mediate inflammatory cytokine 
production in LPS-treated macrophages (18). To evaluate the role of Tmem178 during an 
inflammatory response in vivo, we utilized the endotoxin model of sepsis. Strikingly, Tmem178-
129 
 
/- mice rapidly succumbed to systemic LPS, with the majority of knock-out mice dying within 16 
hours of challenge (Figure 4.2 A). This mortality was associated with a significant increase in 
TNF- levels detected in the serum 2 hours post-LPS administration (Figure 4.2 B). Tmem178-/- 
mice do not present with spontaneous inflammation in vivo, supporting that Tmem178 may be 
most highly expressed and physiologically important during an immune challenge (Supplemental 
Figure 4.2). These in vivo data indicate that Tmem178 is a negative regulator of inflammation, in 
contrast to the pro-inflammatory role played by PLC2.  
Tmem178 restrains inflammatory cytokine production by macrophages  
 To confirm that Tmem178 affects the macrophage inflammatory response in vitro, we 
measured inflammatory cytokine production by WT and Tmem178-/- BMMs in vitro in response 
to adhesion and LPS. Confirming our previous observations, WT BMMs plated on pRGD 
increase TNF-, IL-6, and IL-1 mRNA expression (Figure 4.2 C). Each of these cytokines were 
each markedly increased in Tmem178-/- BMMs however. Similarly, LPS treatment increases 
inflammatory cytokine transcription in WT BMMs as expected, but this response is even 
amplified in Tmem178-null BMMs (Figure 4.2 D). Together with our previous expression 
profiles and in vivo results, these data indicate that Tmem178 acts in a negative feedback loop to 
dampen inflammatory signaling in the macrophage.  
 Tmem178 targets Ca2+-NFAT signaling to repress inflammation 
We next wanted to examine the mechanism by which Tmem178 restrains the pro-
inflammatory response. Adhesion and TLR ligation both activate NF-kB and MAPK signaling 
cascades. We next asked if Tmem178 affects these pathways to modulate inflammation. We first 
plated WT and Tmem178-/- BMMs on pRGD to up-regulate Tmem178 expression in WT cells, 
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and then stimulated the cells with LPS. We find that p-JNK, p-ERK, and p-IKBinduction 
occurs rapidly and equivalently in both genotypes (Figure 4.3 A). NFATc1, however, is higher in 
Tmem178-/- cells prior to LPS stimulation. Activation via integrin or LPS alone also shows a 
similar increase in NFATc1 (Supplementary Figure 4.3).  
Multiple NFAT isoforms are expressed in macrophages and contribute to inflammatory 
response (19). In addition to NFATc1, NFATc3 is also important to the inflammatory response. 
Importantly, NFAT isoforms are regulated at the transcriptional level by binding to and auto-
amplifying expression at its own promoter. We measured NFAT transcripts in peritoneal 
macrophages ex vivo, as well as in BMMs stimulated with LPS, and found that both NFATc1 
and NFATc3 are higher in Tmem178-/- cells (Figure 4.3 B, C).  
 In basal conditions, NFAT is sequestered in the cytosol due to masking of its nuclear 
localization sequence. The Ca2+/calmodulin-dependent phosphatase calcineurin de-
phosphorylates NFAT, inducing a conformational change to allow nuclear translocation. Thus, 
cytosolic Ca2+ fluxes are essential to NFAT activation. We hypothesized that Ca2+ oscillations 
may be amplified in the Tmem178-/- inflammatory macrophage. WT and Tmem178-/- BMMs 
were stimulated with LPS for 16 hours, and then loaded with the Ca2+-binding dye Fura-2. We 
used ratiometric confocal imaging to measure cytosolic Ca2+, as measured by Fura-2 emission 
following alternating excitation at 340 and 380 nm. We found that Ca2+ fluxes were higher in 
Tmem178-/- cells, and a greater percentage of cells display robust Ca2+ fluxes compared to WT 
cells (Figure 4.3 D). Thus, Tmem178 appears to target intracellular Ca2+ signaling to regulate 
inflammation.  
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M1 and M2 macrophage populations participate in MAS 
 In order to evaluate the role of Tmem178 specifically in a clinically relevant, 
macrophage-driven disease, we turned to macrophage activation syndrome (MAS). MAS bears 
many clinical similarities to the inherited disease (fHLH), which is also characterized by 
excessive macrophage infiltration and systemic inflammatory disease with a similar 
inflammatory cytokine profile (20). Jordan et al previously established a mouse model of 
fHLH/MAS utilizing perforin (prf)-/- mice infected with lymphocytic choriomengitis virus 
(LCMV-WE). Prf-/- mice infected with LCMV recapitulate the pathology of MAS and fHLH 
patients (21). Despite the expanded presence of macrophages in this disease, it is unknown if 
macrophages are the drivers of disease through excessive antigen presentation and inflammatory 
cytokine production, or if macrophages are futilely attempting to control the pathology. Thus, we 
first wanted to evaluate the role of macrophages in this model. We administered clodronate-
loaded liposomes (CLL) to specifically deplete macrophages, and confirmed the depletion by 
FACS of F4/80+ cells (Supplemental Figure 4.4). We administered CLL to prf-/- mice 2 days 
prior to LCMV infection, and every 3 days thereafter for the course of infection.  Because 
virally-infected WT mice depleted of macrophages die due to liver failure (22), we used 
liposomes containing PBS as controls in WT and prf-/- mice. As expected, 100% of LCMV-
infected prf-/- mice died within 21 days (Figure 4.4 A). Prf-/- mice with macrophages depleted 
by CLL survived for more than 40 days post-infection, similarly to WT mice. Serum cytokines 
measured on day 10 of infection showed that macrophage depletion strongly reduces IFN- and 
MCP-1 levels (Figure 4.4 B). We also wanted to know if macrophage depletion later in the 
course of infection could cure prf-/- mice of HLH. We began CLL treatment on day 6 after 
LCMV inoculation, as this was the time point when mice showed obvious signs of disease 
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including weight loss, hunched posture, and ruffled fur. Surprisingly, mice treated on day 6 died 
more rapidly, reaching 100% mortality by day 16 (Figure 4.4 C). From these data we 
hypothesized that both pro- and anti-inflammatory macrophages are present during HLH, with 
the latter population playing an essential role to limit the infection later in disease.  
 To examine this possibility, we characterized M1 and M2 macrophage populations during 
the course of infection in prf-/- mice. The livers and spleens of mice were harvested after the 
indicated days of infection. Both M1 (F4/80+MHC Class II + CD86+) and M2 (F4/80+CD206+) 
populations increase in liver (Figure 4.4 D) and spleen (Figure 4.4 E). There is a significant and 
transient increase in M2 macrophages by day 7 of infection in the liver and days 7-10 in the 
spleen. These data suggest that an infiltrating population of anti-inflammatory macrophages is 
important to control disease progression.  
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4.6 Discussion 
Current therapeutics to treat pathological bone loss are widely unsuccessful at addressing 
both the resorptive and inflammatory components of disease. We have previously established the 
fundamental role of PLC2 in regulating both osteoclast differentiation and bone resorption as 
well as the immune cell compartment in arthritic disease (14, 17, 23). PLC2-specific targeting 
to treat inflammatory bone loss is impractical due to its high homology with the ubiquitously 
expressed isoform PLC1. Moreover, we know little about PLC2-dependent regulators of the 
innate inflammatory response. Here we characterized Tmem178 as a PLC2-dependent negative 
regulator of the pro-inflammatory macrophage which acts by repressing Ca2+ oscillations and 
downstream NFAT activation. Tmem178 is also required in vivo to control and repress a 
systemic inflammatory response. Ongoing studies will address the role of Tmem178 in MAS, a 
complicating disorder of arthritis.   
To understand how Tmem178 restrains inflammation, we examined signaling pathways 
that are known to be activated by TLR signaling to promote inflammatory cytokine production. 
Similar to our findings in the osteoclast, Tmem178 deletion did not affect NF-kB or MAPK 
induction, but rather targets Ca2+ fluxes leading to NFAT activation. We found that both Nfatc1 
and Nfatc3 isoforms are increased in Tmem178-/- BMMs. Ca2+ has long been recognized as an 
absolutely essential second messenger for both adaptive and innate responses. Mechanisms of 
calcium signaling in the context of immunity have largely been discovered and characterized in 
the context of the T cell and B cell receptors (24). While not as closely studied, PLC2-
dependent Ca2+ pathways have previously been shown to regulate inflammatory cytokine 
production in macrophages (25-29). Here we show that Tmem178 functions in a novel negative 
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feedback loop downstream of PLCγ2 to repress inflammation, thus building on the 
understanding of how intracellular calcium is regulated during an inflammatory response. 
Importantly, calcineurin inhibitors are widely used as immunosuppressive drugs, and while 
effective, this approach lacks specificity. Here we have characterized a novel and specific 
intrinsic mechanism of targeting calcium signaling in macrophages.  
Circulating and tissue-resident monocyte/macrophage populations can dictate the 
immune response by producing a number of cytokines, both pro- and anti-inflammatory. 
Macrophages have been segregated into “classically activated” M1 and “alternatively activated” 
M2 subtypes. M1 macrophages are strongly pro-inflammatory and anti-tumorigenic through the 
production of IL-1, TNF-, IL-6, and iNOS, as well as enhanced MHC Class II antigen 
presentation capacity. On the other hand, M2 macrophages produce arginase and IL-10 to 
resolve inflammation and promote tissue repair (30). The relative contribution of M1 and M2 
populations in systemic auto-inflammatory disorders including sJIA is not well understood. 
Although sJIA patients have an overall expansion in activated monocytes, they present a mixed 
M1 and M2 phenotype both on an overall and single cell level (31, 32). Thus, a better 
understanding of the intrinsic regulatory mechanisms that control macrophage inflammatory 
responses could be informative to understanding the molecular pathogenesis of sJIA. Here we 
identify a novel negative feedback loop mediated by Tmem178 that is enacted to control the pro-
inflammatory macrophage response. 
The large majority of mortalities associated with sJIA are due to the confounding 
disorder MAS.  MAS patients present with a sudden onset of fever, pancytopenia, and very high 
levels of inflammatory cytokines, TNF-, IL-1, IL-6, IL-18, as well as IFN-g in the serum. 
Strikingly, there is a huge increase in macrophages in the spleen, liver, and bone marrow of these 
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patients. Importantly, MAS is clinically nearly identical to familial hemophagocytic 
lymphohistiocytosis (fHLH), an inherited condition owing to a genetic defect in cytotoxic killing 
by T-cells and NK cells. In particular, patients have been identified with mutations in perforin, 
granzyme B, and vesicular trafficking components required for cytotoxic granule release. While 
some sJIA patients also harbor such genetic mutations that predispose them to MAS, it is not the 
case for all patients.  The cause of MAS is unknown, and other than inherited conditions, there 
are currently no predictive indicators of which subset of sJIA patients will develop MAS. We 
have previously shown that Tmem178 is dysregulated in the context of sJIA, and defective 
Tmem178 expression is associated with excessive osteoclast development. We now show a role 
for Tmem178 in controlling inflammation as well, positioning Tmem178 as an essential 
regulatory component in both the inflammatory and erosive arms of sJIA.  
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4.8 Figure Legends 
Figure 4.1 PLC2 regulates pro-inflammatory gene transcription in macrophages 
A. WT and PLC2-/- BMMs were lifted and re-plated on integrin ligand for 2 and 4 hours. 
Inflammatory cytokines IL-6, IL-1, and TNF- were measured by quantitative RT-PCR, 
with gene expression normalized to the housekeeping gene cyclophilin.  
B. WT and PLC2-/- BMMs were lifted and re-plated on integrin ligand for the indicated 
time points. Whole cell lysates were subjected to SDS-PAGE and Western blot to detect 
p-IKB as a read-out of NF-kB activation.  
C. Gene array of WT and PLC2-/- BMMs plated on integrin ligand pRGD for 2 and 4 
hours. Tmem178 is upregulated in adherent WT BMMs but not highly detected in 
PLCg2-/- BMMs 
D. Quantitative RT-PCR of Tmem178 transcript in untreated WT BMMs or stimulated via 
integrin or TLR, as well as in bone marrow-derived neutrophils, bone marrow dendritic 
cells (DC) and T cells. 
Figure 4.2. Tmem178 negatively regulates the pro-inflammatory response of macrophages  
A. WT and Tmem178-/- mice were treated with 25 mg/kg LPS administered IP and 
monitored for survival. n = 12 WT, 17 Tmem178-/- 
B. Serum TNF-a was measured 2 hours after LPS injection in (A).  
   C-D.Quantitative RT-PCR of inflammatory cytokine transcripts in WT and Tmem178-/- 
 BMMs plated on integrin ligand (C) or treated with 1 ug/ml LPS. TNF-, IL-6 and IL-1 
 expression was normalized to the housekeeping gene cyclophilin.   
 
Figure 4.3. Tmem178 reduces Ca2+ fluxes leading to NFAT induction in pro-inflammatory 
 macrophages 
A. WT and Tmem178-/- BMMs were plated on pRGD for 8 hours, and then stimulated with 
1 ug/ml LPS for the indicated time points. Whole cell lysates were separate by SDS-
PAGE and immunoblotted with the indicated antibodies to detect MAPK and NF-kB 
pathway activation, as well as NFATc1 induction. Pyk2 was detected as a loading 
control.  
   B-C. Nfatc1 and Nfatc3 transcripts were measured by quantitative RT-PCR with values 
 normalized to cyclophilin in resident peritoneal macrophages (B, n = 4/genotype) or 
 BMMs stimulated with 1 ug/ml LPS for 4 hours (C).  
D. Intracellular Ca2+ fluxes in single BMMs treated with 1 ug/ml LPS for 16 hours prior to 
 imaging. Each line traces a single cell, representative of 3 independent experiments.  
 
Figure 4.4. M1 and M2 macrophage populations participate in a mouse model of 
MAS/fHLH 
A. WT and prf-/- mice were infected with LCMV-WE. Prf-/- mice were depleted of 
macrophages by systemic administration of clodronate-loaded liposomes (CLL) prior to 
infection. n = 5/group 
B. Serum IFN- and MCP-1 were measured in mice in (A) on day 10 of infection.  
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C. WT and prf-/- mice were infected with LCMV-WE. Prf-/- mice were depleted of 
macrophages by systemic administration of CLL beginning on day 6 of infection. n = 
5/group 
D-E. Prf-/- mice were infected with LCMV-WE to induce MAS/fHLH. Liver and spleen 
 were harvested after the indicated days of infection to measure surface expression of 
 markers for M1 macrophage (F4/80+MHC Class II + CD86+) and M2 macrophages 
 (F4/80CD206) n = 5/group 
 
Supplemental Figure 4.1 PLC2 catalytic activity is required for adhesion-induced NF-kB 
activation   
BMMs were plated on pRGD for the indicated time points. NF-kB induction in PLC2-/- 
BMMs transfected with WT-PLC2 (left panels), PLC2 catalytic inactive mutant (middle 
panels), or PLC2 SH2 mutant (right panels). 
 
Supplemental Figure 4.2. Tmem178-/- mice do not display an inflammatory phenotype in 
basal conditions 
A. Serum cytokine levels in WT and Tmem178-/- mice in basal conditions. WT n = 5, 
Tmem178-/- n = 9 
B-C. M1 and M2 macrophages detected in the peritoneum and spleen of un-manipulated 
 WT and Tmem178-/- mice 
 
Supplemental Figure 4.3. Tmem178 specifically affects NFATc1 in pro-inflammatory 
macrophages 
A. WT and Tmem178-/- BMMs were stimulated on LPS for the indicated time points. 
Whole cell lysates were separate by SDS-PAGE and immunoblotted with the 
indicated antibodies to detect MAPK activation, as well as NFATc1 induction. Actin 
was detected as a loading control.  
B. WT and Tmem178-/- BMMs were plated on pRGD for the indicated time points. 
NFATc1 was detected by Western blot of whole cell lysates. Total ERK was 
detected as loading control.  
Supplemental Figure 4.4. Confirmation of macrophage depletion by clodronate loaded 
liposomes 
Flow cytometry to detect F4/80+ cells in the spleen of PBS- or clodronate-treated mice. 
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5.1 Conclusions and future directions 
In this work, we have identified Tmem178 as a new PLCγ2-dependent gene and 
demonstrated the first known function of Tmem178 in any cell type. Tmem178 is not 
similar to any other “Tmem” molecules, or any other transmembrane proteins expressed 
in the OC or macrophage. Other than its Claudin-2 domain, which is not known to harbor 
any intrinsic function, Tmem178 does not contain any conserved structural domains or 
similarity to other Ca2+-related proteins. Moreover, we found that Tmem178 expression 
is induced downstream of PLC2-dependent pro-osteoclastogenic and pro-inflammatory 
pathways, but Tmem178 actually acts in a negative feedback loop to restrain both 
osteoclastogenesis and inflammatory cytokine production. Thus, the findings presented in 
this thesis were neither obvious nor expected. 
Current therapeutics to treat pathological bone loss are widely unsuccessful at 
addressing both the resorptive and inflammatory components of disease. Moreover, even 
patients who respond favorably to anti-inflammatory agents can suffer from progressive 
joint disease. Thus, an essential question in the field is how we could simultaneously 
target activation of both immune cells and osteoclasts. Our lab previously undertook 
studies to identify common signaling components shared in the osteo-immune system and 
successfully identified PLCγ2 as such a critical signaling molecule. PLCγ2-/- mice are 
protected from inflammatory bone loss due to a blockade in both bone resorption as well 
as immune cell activation. While PLCγ2 seems an appealing therapeutic target, its 
extensive homology with other PLC isoforms presents a challenge for specific targeting 
in vivo.  
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We devised a strategy to specifically target PLCγ2 via its unique SH2 domains. 
By ectopically expressing a construct comprised of the tandem SH2 domains of PLCγ2, 
we were able to inhibit osteoclastogenesis in vitro by impeding protein scaffolding at 
RANK. Importantly, expression of this (N+C)-SH2 construct in vivo via an adenoviral 
vector also successfully repressed inflammatory osteolysis (1). This approach, however, 
did not block inflammation in vivo.  Therefore, we must focus on characterizing unique 
downstream effectors of PLCγ2 which modulate osteo-immune activation.  
Using a gene array approach to identify PLCγ2-dependent genes, we found that 
the uncharacterized protein Tmem178 was highly induced in stimulated WT cells but not 
in PLCγ2-/- cells. Tmem178 expression is upregulated in both osteoclasts in response to 
RANKL, as well as in macrophages in response to adhesion or TLR ligation. Importantly, 
Tmem178 expression appears to be limited to these compartments, and we do not 
detected Tmem178 transcript in osteoblasts, neutrophils, or T cells. Thus, Tmem178 may 
be the specific, PLCγ2 downstream effector we were seeking which could control osteo-
immune activation. In striking contrast to the osteopetrotic PLCγ2-/- mice, Tmem178-
null mice present with low bone mass in basal conditions and exaggerated osteoclast 
formation and bone loss during inflammatory arthritis. In vitro, Tmem178-/- cells display 
an enhanced ability to form osteoclasts. Thus, Tmem178 is a surprising negative 
regulator of osteoclastogenesis. Mechanistically, Tmem178 specifically targets NFATc1 
induction in osteoclasts by controlling ER Ca2+ mobilization.  
Ca2+ is a ubiquitous signaling mediator in nearly all cell types and thus calcium 
signaling must be regulated in all cell types, so why is Tmem178 so unique and its 
expression seemingly very limited? In primary cells, elegant studies have been performed 
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to characterize Ca2+ signaling mechanisms in the context of the T and B cell receptor, or 
innate immune cells such as mast cells. In these cell types, receptor ligation induces an 
acute and transient spike in cytosolic Ca2+, leading to an immediate signaling event. This 
is not the case in OCs, however, where intracellular Ca2+ fluxes are sustained over a 
longer time course.  Moreover, the amplitude and duration of dynamic Ca2+ signals have 
been shown to differentially modulate activation of various transcription factors.  The OC 
uses Ca2+ to turn on NFATc1 activation. NFAT proteins have enhanced Ca2+ sensitivity 
compared to other transcription factors such as NF-kB or JNK, which enables NFAT 
transcriptional activation by low Ca2+ levels (2). In the OC, a low but prolonged Ca2+ 
signal induces NFATc1 nuclear translocation and long-lasting nuclear localization 
throughout osteoclastogenesis. Therefore, it is conceivable that the OC requires 
additional regulatory mechanisms to carefully buffer ongoing and subtle changes in 
cytosolic Ca2+.  
Interestingly, Tmem178 couples to the ER Ca2+ sensor Stim1, which is most well-
characterized for its coupling to Orai1 to activate store-operated Ca2+ entry (SOCE).  
Surprisingly, we did not detect a direct effect of Tmem178 expression on SOCE, nor did 
we find that Tmem178 interacts with Orai1 or modulates Orai1-Stim1 coupling. These 
findings that Tmem178 associates specifically with Stim1 independent of SOCE raise the 
possibility that Stim1 is also participating in ER Ca2+ release in OCs. In recent studies, 
Stim1 has been shown to play a possible role in affecting ER Ca2+ release through the 
IP3R channels (3, 4). IP3R activity is highly regulated by multiple adaptor proteins as 
well as kinases which phosphorylate IP3R to increase its sensitivity to IP3 (5). We have 
not been able to detect an association between Tmem178 and endogenous IP3Rs, 
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however. It is possible that Tmem178-Stim1 is affecting Ca2+ release through the 
ryanodine receptor whose regulation is less well-understood than IP3Rs (6).  
Further studies are underway to understand which functional domain(s) of 
Tmem178 are important to its function and coupling to Stim1, and vice versa. While very 
little information is available about Tmem178 structure, we know it contains 1 claudin-2 
domain. Structure/function studies showed that the C-terminal tail of claudin-2 domain-
containing proteins is required for their function, and phosphorylation of a Serine residue 
in the C-terminus was also shown to promote membrane localization and control ion 
transport  (7-9). Therefore, we have generated a C-terminus truncation mutant of 
Tmem178 to evaluate its ability to bind to Stim1 and repress ER Ca2+ release. 
 Extensive structure-function experiments delineated the mechanism of Stim1 
activity during SOCE. In the ER luminal portion of the protein, Stim1 harbors a Ca2+-
binding EF hand as well as a SAM domain which facilitates protein-protein interactions. 
When ER Ca2+ stores are depleted, Ca2+ dissociates from the EF hand and causes EF-hand 
and SAM domains to interact between Stim1 molecules. This induces a conformational 
change in the cytoplasmic domain leading to the unfolding and extension of the C-
terminus; this is the “activated” Stim1 dimer. Stim1 continues to oligomerize as it is re-
localizing to the ER-plasma membrane junction. At the C-terminus of Stim1, the STIM-
Orai1 activating region (SOAR) binds and activates Orai1, allowing CRAC channel 
activation (10). The domains of Stim1 which interact with IP3Rs have not been 
identified. By expressing the individual domains of Stim1, we can determine which 
regions are necessary and sufficient to interact with Tmem178. It is also necessary to 
understand if the same regions of Stim1 which modulate Orai1 activation, namely the 
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SAM and SOAR domains, are necessary to associate with Tmem178. Moreover, we have 
not assessed the temporal or spatial aspects of the Tmem178-Stim1 interaction. In future 
live cell imaging studies, we must understand when the Tmem178-Stim1 interaction 
occurs downstream of receptor signaling, and how this affects Stim1 translocation that is 
necessary for SOCE. We have observed that Tmem178 does not affect SOCE, suggesting 
that perhaps separate pools of Stim1 exist in the ER to regulate different intracellular 
Ca2+ events. 
Having confirmed that Tmem178 is a negative regulator of osteoclastogenesis in 
vitro and in vivo, we sought a role for Tmem178 in human disease. We turned to 
systemic juvenile idiopathic arthritis (sJIA), as it is a predominantly monocyte-mediated 
auto-inflammatory disordered associated with progressive joint disease. Using the plasma 
from sJIA patients, we found that Tmem178 is strikingly down-regulated by sJIA plasma, 
permitting more exuberant osteoclastogenesis. Importantly, patients who presented with 
active erosive disease were each associated to significantly down-regulated Tmem178 
levels in vitro. While our sample size at this point is too small to draw a correlation 
between defective Tmem178 expression and active joint erosion, it will be interesting in 
the future to see if Tmem178 levels could be a predictive biomarker of patients who will 
develop progressive joint disease.  
 sJIA is unique from other JIA subtypes in its dependence on the innate immune 
response, specifically monocytes, in disease pathogenesis with a limited role of the 
adaptive immune response. sJIA is not associated with MHC allele susceptibility or 
rheumatoid factor. In fact it is so distinct from other JIA subtypes that the categorization 
is considered by some to be a misnomer. Intriguingly, M2-like monocytes appear during 
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episodes of disease flare and persist into the transition to a quiescent state, suggesting that 
this M2 population arises in an attempt to ameliorate the systemic inflammatory 
environment (11, 12). In fact, it is still unknown whether the excessive pro-inflammatory 
response or defective anti-inflammatory response truly underlies the pathologies of sJIA.  
We know that Tmem178 expression is specific to activated myeloid cells, 
including macrophages exposed to inflammatory stimuli such as TLR ligands. The trigger 
of sJIA is unknown, but endogenous TLR ligands are possible activators of the auto-
inflammatory reaction. In studying the role of Tmem178 in the pro-inflammatory 
macrophage, we found that Tmem178 limits inflammatory cytokine release in response to 
both adhesion and LPS stimulation. Similarly, Tmem178-/- mice succumb faster to 
endotoxin-induced sepsis. These data position Tmem178 as a negative regulator of the 
pro-inflammatory macrophage response. While we have found that Tmem178 is down-
regulated by sJIA serum during osteoclastogenesis, we have yet to characterize the role of 
Tmem178 in the inflammatory component of sJIA. It is possible that Tmem178 
expression is also decreased in circulating inflammatory monocytes of sJIA patients. This 
reduction of Tmem178 would ramp up the pro-inflammatory response and hinder the 
anti-inflammatory attempts of M2-like monocytes. In these conditions, Tmem178 levels 
may also be a marker of the subset of sJIA patients who develop an acute, potentially 
fatal disorder known as macrophage activation syndrome (MAS).  
While the cause of MAS is uncertain, it is possible that a dysregulated adaptive 
immune response to an infectious trigger stimulates the over-active macrophage 
population. It is actually unknown how the macrophage is participating in disease. It is 
possible that macrophages are attempting to control the adaptive immune response. On 
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the other hand, macrophages may be driving the pathology by facilitating excessive 
antigen presentation to T cells and producing inflammatory cytokines. The specific 
contribution of M1 and M2 macrophages during a course of MAS has not yet been 
studied.  
MAS bears many clinical similarities to the inherited disease familial 
hemophagocytic lymphohistiocytosis (fHLH), which is also characterized by excessive 
macrophage infiltration and systemic inflammatory disease with a similar inflammatory 
cytokine profile (13). We used a mouse model of fHLH to define the requirement of 
macrophages in this disease (14).  In preliminary studies, we have found that both M1 
and M2 macrophage populations increase during the LCMV-induced model of MAS. In 
fact, limiting the M1 response early in disease is sufficient to protect mice from disease, 
while eliminating the infiltrating anti-inflammatory M2 population accelerates mortality. 
Could Tmem178 be participating in these distinct phases of macrophage activity? To this 
end, we have generated Tmem178-perforin double knock out mice in which we can 
induce MAS. If Tmem178 is important to the attempts to control MAS early in the course 
of disease, the double knock out mice will succumb faster than perforin-null mice alone. 
If so, it would be interesting to measure Tmem178 transcript levels in the monocytes of 
sJIA patients who go on to develop MAS.  
In sum, this work defines the function of Tmem178 as novel regulator of osteo-
immune activation. In contrast to our expectations, these studies identified a novel 
negative feedback loop acting via Ca2+ to control myeloid cell activation. As this is the 
first work describing Tmem178 in any cell type, there are many more studies to be done 
to fully understand the function of Tmem178 in homeostasis and disease, particularly in 
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sJIA. Most importantly, we identified a new pathway of Ca2+ regulation in myeloid cells 
as a mechanism that can control both joint erosion and excessive inflammation.  
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